SE539512C2 - Compounds and methods of treating bacterial infections - Google Patents

Abstract

The invention relates to compounds of Formula I,wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula I in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.

Description

COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS TECHNICAL FIELDThis invention relates to compounds of Formula l, and the use of a compound of Formula I in the manufacture of a medicament for the treatment of a bacterial infection in a subject.

BACKGROUND ART A marked increase in prevalence of multi-drug resistance in disease-causing Gram- positiveG+ve (inter a|ia Staphylococcus aureus, Enterococcus spp., Streptococcus pneumoniae,Clostridium difficile, Mycobacterium tuberculosis) and Gram-negative bacteria (inter a|iaKlebsiella spp., Neisseria gonorrhoeae, Acinetobacter spp., Campylobacter spp.,Enterobacter spp., Pseudomonas aeruginosa, Salmonella spp., Shigella spp.) has coincidedWith an unprecedented global decline in investment in new anti-infective drugs. There arefew currently registered alternatives for multidrug resistant (MDR) bacterial infections, forcingclinicians to consider older generation drugs such as colistin with narrow spectrum andconsiderable potential for toxic side-effects. ln addition, there are fewer novel classes of anti- infective therapeutics moving through the drug development pipeline.

Since the year 2000, a period of almost 15 years, only 5 novel mode of action (MOA)antibacterial agents have been approved by the US FDA - linezolid (an oxazolidinone) in2000, daptomycin (a lipopeptide) in 2003, retapamulin (a pleuromutilin) in 2007, fidaxomicin(a macrolide tiacumicin) in 2011 , and bedaquiline (a diarylquinoline) in 2012. No novel MOAantibacterial agents were approved in 2013 and to date in 2014 only tedizolid anddalbavancin, both analogues of existing classes, have been recommended for approval inthe US. While there are more than 300 anti-infective medicines in various stages ofdevelopment, the large majority of these medicines are previously approved antibacterial compounds or their derivatives that are undergoing studies for new indications.

Furthermore, the prevalence of multidrug-resistance in animal-specific pathogens togetherwith greater regulation of the registration and usage of antimicrobials in animals, has causedveterinarians to become increasingly reliant on the traditional classes of antimicrobial agents.The risk of transfer of MDR zoonotic organisms from animals to humans has also led to callsfor further restrictions on the usage of some recently registered antibacterial drugs such as the fluoroquinolones and the third and fourth generation cephalosporins.

Epidemiology of antibacterial resistance development in pathogens of humans and animals 2 Much of the evolution in resistance development is driven by changes in the epidemiology ofkey MDR organisms. Once only restricted to human hospitals and aged care facilities,methicillin resistant Staphylococcus aureus (MRSA) strains are now being isolated from thecommunity in alarming proportions. Furthermore, community-acquired MRSA strains aremore likely to carry the Panton-Valentine leukocidin (PVL) toxin, a virulence factor linked toskin and soft tissue lesions as well as a rapid, fulminating, necrotizing pneumonia withsignificant associated mortality. Recently MRSA strains have become host-adapted inseveral key animal species including livestock, horses and companion animals and regularcases of human-to-animal and animal-to-human transfer are being documented. This hasimportant consequences for strain transmission and public health. A recent survey of 751Australian veterinarians for MRSA nasal carriage found that a remarkable 21 .4% of equineveterinarians were MRSA-positive compared to 4.9% of small animal veterinarians and 0.9%of veterinarians with little animal contact. These ecological shifts of MRSA together with theemergence of resistance to new drugs developed specifically for MRSA such as linezolid,confirm that new MRSA anti-infectives are urgently needed. Furthermore, hospitals that usevancomycin for treating MRSA then have to contend with outbreaks of vancomycin-resistantenterococci (VRE) infections in their patients, once again with limited alternative antimicrobial choices.

The World Health Organisation has identified antibiotic resistance as one of the three majorfuture threats to global health. A recent report from the US Centers for Disease Control andPrevention (CDC) estimated that "in the United States, more than two million people aresickened every year with antibiotic-resistant infections, with at least 23,000 dying as a result."The extra medical costs, in the USA alone, associated with treating and managing a singlecase of antibiotic-resistant infection are estimated to be between US$18,588 and US$29,069per year resulting in an overall direct cost to the US health system of over US$20 billionannually. ln addition, the cost to US households in terms of lost productivity is estimated atover US$35 billion per annum. Twenty five thousand patients in the European Union (EU)still die annually from infection with MDR bacteria despite many EU countries having world'sbest practice hospital surveillance and infection control strategies. The EU costs from healthcare expenses and lost productivity associated with MDR infections are estimated to be at leastê1.5 billion per year.

There is an unmet clinical need for antibacterial agents with novel mechanisms of action tosupplement and replace currently available antibacterial agents, the efficacy of which is increasingly undermined by antibacterial resistance mechanisms. There additionally remains a need for alternative antibacterials in the treatment of infection by multi-resistant bacteria.However, as reported by the lnfectious Diseases Society of America and the EuropeanCentre for Disease Control and Prevention, few new drugs are being developed that offerpromising results over existing treatments (lnfectious Diseases Society of America 2010,Clinical lnfectious Diseases, 50(8): 1081 -1083).

Ayer WA & Villar JDF Can J Chem 63,1161 (1985) describe an enolic natural productisolated from the fungus Lachnellula fuscosanguinea, which they term lachnellulic acid:,H~ f \ \ I o oThe compound is active against the Dutch Elm disease fungus. Note that the alkyl chain adjacent the enolic keto function is longer than the chain adjacent the lactone.

Kong et al, J. Nat. Prod. 2005 68, 920-923 describe natural products isolated from a Pseudomonas species associated with a Pacific marine sponge, which they term pseudopyronines A & B:OH Pseudopyronine A: R = (CH2)3CH3Pseudopyronine B: R = (CH2)5CH3 The compounds are described as having “moderate to poor” antibacterial activities, but areunstable and degrade to a hydroxyfuranone species. Note that the pyranone ring has tvvounsaturated bonds. ln a related paper, Singh et al J Antibiotics 56 No 12 1033-1044 (2003),the antibacterial activity of the compounds is believed to derive from inhibition of the bacterialfatty acid biosynthesis pathway, in a somewhat similarfashion to the antibacterial agent triclosan.

Miyakado et al Chem Lett 10 1539-42 (1982) describes the isolation of natural products fromthe plant Podophyllum peltatum, which they term podoblastin A: OH O \ R R: '(CH2)12CHa-CH CH O O ( 2)1o 3 -(CH2)6CH=CH2 4 The compounds are said to be active against the fungus Pyricularia oryziae. Note that thealkyl chain adjacent the carbonyl is markedly longer than the alkyl chain adjacent the lactone.

The discussion of the background art set out above is intended to facilitate an understandingof the present invention only. The discussion is not an acknowledgement or admission thatany of the material referred to is or was part of the common general knowledge as at thepriority date of the application.

SUMMARY OF INVENTIONAccording to one aspect of the invention, there is provided a compound of Formula l, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof: o oR3o | R2Ri oR4Formula I wherein R1 is C2-C20alkenyl comprising one to three unsaturated bonds; Rz is C1-C20alkyl, C2-C20alkenyl, C2-C20alkynyl, C1-C6alkoxyC1-C3alkyl, cyclopropylmethyl,cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl; Rs is a bond along with the adjacent carbon defining a keto group, Rs, C(O)R5, CRaRbORs,cRaRboc(o)R5, cRaRboc(o)oR5 0rc(o)cHR7NH2; R4 is Rs, c(o)R5, cRaRboRfi, cRaRboc(o)R5, cRaRboc(o)oR5 0rc(o)cHR7RNH2; Rs and RB are independently selected from H, C1-C6alkyl, Cg-Cßcycloalkyl and C3-C6cycloalkylC1-C3alkyl, wherein the C1-C6alkyl or cycloalkyl is optionally substituted with halo,hydroxy, C1-C4alkoxy, C1-C4haloalkyl, hydroxyC1-C4alkyl, C1-C4alkylcarbonyl, SH, SMe,COOH, COOC1-C4alkyl and CONHZ; R7 is H, C1-C6alkyl, Cg-Cßcycloalkyl and Cg-CßcycloalkylC1-C3alkyl, wherein the C1-C6alkyl orCg-Cßcycloalkyl is optionally substituted with halo, hydroxy, phenyl, C1-C4alkoxy, C1-C4haloalkyl, hydroxyC1-C4alkyl, C1-C4alkylcarbonyl, SH, SMe, COOH, COOC1-C4alkyl andCONH¿ Ra and Rb are independently selected from H and methyl; or a pharmaceutically acceptable salt, stereoisomer, N-oxide or hydrate thereof. 5 Rs is C2-C20alkenyl comprising one to three unsaturated bonds which is optionally substitutedas defined above. ln sub-embodiments, Rs is C6-C12alkenyl, such as hexenyl, heptenyl,octenyl, decenyl, undecenyl or dodecenyl, including those with one unsaturated bond, and especially those in the 1-position.

The bond connecting Rs to the pyran ring is chiral, and the invention includes certainembodiments Which are racemic at this position, or embodiments enantiomerically enrichedwith the S or R diastereomer, for example 75% enantiomerically enriched as regards onediastereomer, typically greater than 90% enantiomerically enriched, such as greater than 95% enantiomerically enriched. ln certain embodiments, Rs is C1-C20alkyl which is optionally substituted as defined above. lnsub-embodiments, Rs is C1-C6alkyl, including methyl, ethyl, n-propyl, isopropyl, n-butyl,isobutyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl, any of which alkyl species beingoptionally substituted with 1, 2 or where valance permits 3 substituents independentlyselected from C1-C4 alkyl, C1-C4 haloalkyl, halo, hydroxy, C1-C4alkoxy, C1-C4hydroxyalkyl andC1-C4alkylcarbonyl. ln certain embodiments, Rs is a bond to the adjacent carbon thereby defining a keto group. lnother embodiments Rs is H, it being appreciated that when Rs is H, a depiction of thecompound as a delocalized structure as illustrated below is appropriate:Ho” \o | || |L J Embodiments in which Rs is H in the therapeutic form represent a convenient handle to allowthe compound to be derivatised with conventional prodrug moieties, such as C(O)Rs (forexample where Rs is methyl, isopropyl, cyclopropyl or terf-butyl, any of Which may beoptionally fluorinated), -CRsRsORs, (for example Where Rs and Rs are both H or both methyland Rs is methyl, isopropyl, cyclopropyl or terf-butyl, any of which may be fluorinated), -CRsRsOC(O)Rs, (for example Where Rs and Rs are both H or both methyl and Rs is methyl,isopropyl, cyclopropyl or terf-butyl, any of which may be optionally fluorinated), -CRsRsOC(O)ORs, (for example where Rs and Rs are both H or both methyl and Rs is methyl,isopropyl, cyclopropyl or tert-butyl, any of which may be optionally fluorinated) or- C(O)CHR7NH2, wherein Rs is as stated above,for example Rs is the side chain of an L-amino acid such as the side chain of alanine, valine, leucine or isoleucine. ln alternativeembodiments Ra remains bound to the compound of formula I in its therapeutic form, forexample when Ra is C1-C6alkyl, (for example methyl, ethyl, isopropyl, cylopropyl or terf-butyl, any of which may be optionally fluorinated) ln certain embodiments Ra is H. Compounds wherein Ra is H in the therapeutic formrepresent a convenient handle to allow the compound to be derivatised with conventionalprodrug moieties, such as C(O)Ra (for example where Ra is methyl, isopropyl, cyclopropyl orterf-butyl, any of which may be optionally fluorinated), -CRaRaORa, (for example where Raand Ra are both H or both methyl and Ra is methyl, isopropyl, cyclopropyl or terf-butyl, any ofwhich may be fluorinated), -CRaRbOC(O)Ra, (for example where Ra and Ra are both H orboth methyl and Ra is methyl, isopropyl, cyclopropyl or terf-butyl, any of Which may beoptionally fluorinated), -CRaRaOC(O)ORa, (for example where Ra and Ra are both H or bothmethyl and Ra is methyl, isopropyl, cyclopropyl or terf -butyl, any of which may be optionallyfluorinated) or-C(O)CHR7NH2, wherein Ra is as stated above,for example Ra is the side chainof an L-amino acid such as the side chain of alanine, valine, leucine or isoleucine. lnalternative embodiments Ra remains bound to the compound of formula I in its therapeuticform, for example when Ra is C1-C6alkyl, (for example methyl, ethyl, isopropyl, cylopropyl or terf-butyl, any of which may be optionally fluorinated).

According to another aspect of the invention, there is provided a method of treating,eliminating and/ or preventing a bacterial colonisation or infection in a subject, the methodcomprising the step of administering a therapeutically effective amount of a compound ofFormula I, or a therapeutically acceptable salt thereof, to the subject. The method of treating,eliminating and/ or preventing a bacterial infection or colonisation in a subject, may alsocomprise the administration of the pharmaceutical or veterinary compositions of theinvention. Of especial interest is the decontamination of patients carrying MRSA by topical use of a compound of Formula l.

According to a further aspect of the invention, there is provided the use of a compound ofFormula I, or a therapeutically acceptable salt thereof, in the manufacture of medicament the treatment of a bacterial colonisation or infection in a subject.

The subject may be any subject capable of colonisation and infection by bacteria. The subject may be mammalian, or may be piscine or avian. Preferably, the subject is selected from the group comprising, but not limited to, human, canine, feline, bovine, ovine, caprine, other ruminant species, porcine, equine, avian, or piscine.

The compound of Formula I may be administered to the subject in a dose selected from thegroup comprising 0.1 mg/kg to 250 mg/kg body weight, typically 1 mg/kg to 100 mg/kg bodyweight, and more generally 5 mg/kg to 50 mg/kg body weight. Titration of dosage range tosuit the infection and size and physical condition of the patient is readily achieved by theskilled general practitioner or veterinary physician. The compound of Formula I may beadministered to the subject using a dosing schedule selected from the group consisting of:hourly, 3 times daily; twice daily; daily; every second day; twice weekly; once weekly; oncefortnightly; once monthly; once every two months or by constant rate or variable rate infusion.Preferably, the compound of Formula I is administered until colonisation or the signs and symptoms of infection or colonisation have at least been partially treated or alleviated.

In one embodiment, the concentration of compound of Formula I (or a metabolite) in thesubject's blood after treatment is within a range selected from the group comprising, but notlimited to: between 0.1 and 10 ug/mL at 2 hours, 1 and 200 pg/mL after 12 hours; between0.1 and 5 ug/mL after 24 h; between 0.01 and 2 ug/mL after 48 hours; between 0.0001 and 1ug/mL after 72 h. Preferably, the concentration is selected from the group comprising, but notlimited to: less than 200 ug/mL after 12 hours; less than 5 ug/mL after 24 hours; less than 1ug/L after 48 hours and less than 0.5 ug/mL after 72 hours. Selection of therapeutic dosingrange and regime and titration to suit the particular infection and size and physical condition of the patient is readily achieved by the skilled general practitioner or veterinary physician.

When administered to a patient, topical formulations are envisaged, and may e.g. beconvenient in relation to MRSA. Ointments, creams, wet wipes, sprays, and eye drops arealternative and illustrative ways of administrering the compound according to the invention. lnone embodiment, the compound according to the invention is administered by catheter to the bladder of the patient.

The bacterial agent causing the bacterial infection may be a Gram-positive bacterial agentselected from the group comprising, but not limited to, Staphylococcus spp, Streptococci,Enterococcus spp, Leuconostoc spp, Corynebacterium spp, Arcanobacteria spp, Trueperellaspp, Rhodococcus spp, Bacillus spp, Anaerobic Cocci, Anaerobic Gram-PositiveNonsporulating Bacilli, Actinomyces spp, Clostridium spp, Nocardia spp, Erysipelothrix spp, Listeria spp, Kytococcus spp, Mycoplasma Spp, Ureaplasma Spp, 'and Mycobacterium spp. ln one embodiment, the bacterial agent is Gram-positive and is selected from the groupcomprising, but not limited to, Staphylococcus spp. Examples of Staphylococcus spp includeStaphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus lugdunensis,Staphylococcus saprophytics, Staphylococcus auricularis, Staphylococcus capitis,Staphylococcus caprae, Staphylococcus carnosus, Staphylococcus cohnii, Staphylococcushominis, Staphylococcus pasteuri, Staphylococcus pettenkoferi, Staphylococcus pulvereri,Staphylococcus saccharolyticus, Staphylococcus simulans, Staphylococcus schieiferi,Staphylococcus warneri, Staphylococcus xyiosus, Staphylococcus arlettae, Staphylococcuscaseolyticus, Staphylococcus chromogenes, Staphylococcus condimenti, Staphylococcusdelphini, Staphylococcus equorum, Staphylococcus felis, Staphylococcus fleurettii,Staphylococcus gallinarum, Staphylococcus hyicus, Staphylococcus intermedius,Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lutrae, Staphylococcusmuscae, Staphylococcus nepalensis, Staphylococcus piscifermentans, Staphylococcuspseudintermedius, Staphylococcus sciuri, Staphylococcus simiae, Staphylococcus succinus, and Staphylococcus vitulinus. ln another embodiment, the bacterial agent is Gram-positive and is selected from the groupcomprising, but not limited to, Streptococcus spp. Examples of Streptococcus spp includeStreptococcus agalactiae, Streptococcus alactolyticus, Streptococcus anginosus,Streptococcus canis, Streptococcus constellatus, Streptococcus cricetus, Streptococcuscristatus , Streptococcus downei, Streptococcus dysgalactiae subs p. dysgalactiae,Streptococcus dysgalactiae subsp. equisimilis, Streptococcus equi subsp. equi, Streptococcus equi subsp. zooepidemicus, Streptococcus ferus, Streptococcus gallolyticus subsp. gallolyticus (formerly Streptococcus bovis biotype i), Streptococcus gallolyticus subsp. pasteurianus (formerly Streptococcus bovis biotype ii/2), Streptococcus gordonii,Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus infantarius,Streptococcus infantarius subsp infantarius, Streptococcus infantis, Streptococcus iniae,Strepto°<>ccus intermedius, Streptococcus lutetiensis (formerly Streptococcus bovis biotypeii.1), Streptococcus macaccae, Streptococcus mitis, Streptococcus mutans, Streptococcusoralis, Streptococcus orisratti, Streptococcus parasanguinis, Streptococcus peroris,Streptococcus pneumoniae, Streptococcus porcinus, Streptococcus pseudintermedius,Streptococcus pyogenes, Streptococcus ratti, Streptococcus salivarius, Streptococcussanguinis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thermophilus,Streptococcus vestibularis, and Nutritionally Variant (Deficient) Streptococci (Abiotrophia defectiva, Granulicatella adiacens, Granulicatella elegans, and Granulicatella para-adiacens) and related species such as Rothia mucilaginosa (formerly Stomatococcus mucilaginosus ) and Pediococcus. ln another embodiment, the bacterial agent is Gram-positive and selected from the groupcomprising, but not limited to, Enterococcus spp. Examples of Enterococcus spp includeEnterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Enterococcusdurans, Enterococcus avium, Enterococcus raffinosus, Enterococcus pallens, Enterococcusgilvus, Enterococcus cecorum, Enterococcus malodoratus, Enterococcus italicus,Enterococcus sanguinicola, Enterococcus mundtii, Enterococcus casseliflavus/flavescens,Enterococcus dispar, Enterococcus hirae, Enterococcus pseudoavium, and Enterococcus bovis. ln another embodiment, the bacterial agent is Gram-positive and selected from the groupcomprising, but not limited to, Leuconostoc spp. Examples of Leuconostoc spp includeLeuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Leuconostoc paramesenteroides, Leuconostoc citreum, and Leuconostoc lactis. ln another preferred embodiment, the bacterial agent is Staphylococcus aureus, and/or strains known to be resistant such as MRSA.

The bacterial agent causing the bacterial infection may be a Gram-negative bacterial agentselected from the group comprising, but not limited to, Neisseria spp, Moraxella spp,Escherichia spp, Klebsiella spp, Proteus spp, Pseudomonas spp, Salmonella spp, Shigellaspp, Campylobacter spp, Helicobacter spp, Bacteroides spp, Yersinia spp, Vibrio spp, Bordatella spp and Legionella spp.

The bacterial agent causing the bacterial infection might be an anaerobic bacteria, aspirochete or other form of bacteria including Clostridium spp, Borrelia spp, Chlamydia spp and Mycoplasma spp. ln another preferred embodiment, the bacterial agents are resistant to one or severalantibiotics in present use and may be selected from, but not limited to, Clostridium difficile,carbapenem-resistant Enterobacteriaceae, Neisseria gonorrhoeae, multidrug-resistantAcinetobacter, drug-resistant Campylobacter, extended spectrum beta-lactamase producingEnterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, drug-resistant Salmonella, drug-resistant Shigella and drug-resistant Tuberculosis. ln another preferred embodiment, the bacterial agent is resistant to a compound selectedfrom the group comprising: one or more of aminoglycosides (for example gentamicin);ansamycins {for example rifampicin); anti-MRSA cephalosporins (for example ceftaroline);anti- staphylococcal ß-lactams (or cephamycins) (for example oxacillin or cefoxitin);carbapenems (for example ertapenem, imipenem, meropenem or doripenem); non-extendedspectrum cephalosporins; 1 st and 2nd generation cephalosporins (for example cefazolin orcefuroxime); extended-spectrum cephalosporins; 3rd and 4th generation cephalosporins (forexample cefotaxime or ceftriaxone); cephamycins (for example cefoxitin or cefotetan);fluoroquinolones (for example ciprofloxacin or moxifloxacin); folate pathway inhibitors (forexample trimethoprim- sulphamethoxazole); fucidanes (for example fusidic acid);glycopeptides (for example vancomycin, teicoplanin or telavancin); glycylcyclines (forexample tigecycline); lincosamides (for example clindamycin); lipopeptides (for exampledaptomycin); macrolides (for example erythromycin); oxazolidinones (for example linezolid ortedizolid); phenicols (for example chloramphenicol); phosphonic acids (for examplefosfomycin); streptogramins (for example quinupristin-dalfopristin); and tetracyclines (for example tetracycline, doxycycline or minocycline). ln another preferred embodiment, the bacterial agent is Streptococcus pneumoniae. TheStreptococcus pneumoniae may be a strain that is resistant to one or more of ß-lactams and macrolides. ln another preferred embodiment, the bacterial agent is Streptococcus pyogenes. ln another most preferred embodiment, the bacterial agent is Streptococcus agalactiae. ln another most preferred embodiment, the bacterial agent is either Enterococcus faecium orEnterococcus faecalis. The Enterococcus faecium or Enterococcus faecalis may be a strainthat is resistant to aminoglycosides (for example gentamicin (high level) or streptomycin (forexample streptomycin (high level)); carbapenems (for example imipenem, meropenem ordoripenem); fluoroquinolones (for example ciprofloxacin, levofloxacin or moxifloxacin);glycopeptides (for example vancomycin or teicoplanin); glycylcyclines (for exampletigecycline); lipopeptides (for example daptomycin); oxazolidinones (for example linezolid);penicillins (for example ampiciilin); streptogramins (for example quinupristin-dalfopristin); tetracycline (for example doxycycline or minocycline). 11 ln another embodiment, the bacterial agent is Clostridium difficile.

The bacterial infection in the subject may cause a disease selected from the groupcomprising, but not limited to, nosocomial pneumonia caused by Staphylococcus aureus(MDR, XDR, PDR or methicillin-susceptible or -resistant strains), or invasive pneumococcaldiseases such as pneumonia, bronchitis, acute sinusitis, otitis media, conjunctivitis,meningitis, bacteremia, sepsis, osteomyelitis, septic arthritis, endocarditis, peritonitis,pericarditis, ce||u|itis, and brain abscess caused by Streptococcus pneumoniae (includingmulti-drug resistant strains [MDRSP] such as those resistant to ß-lactams and macrolides),complicated skin and skin structure infections, including diabetic foot infections, with orwithout concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptibleand -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae, uncomplicatedskin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptibleand -resistant strains) or Streptococcus pyogenes, community-acquired pneumonia causedby Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP], includingcases with concurrent bacteraemia, or Staphylococcus aureus (methicillin-susceptible and -resistant strains) and Staphylococcus aureus bloodstream Infections (bacteraemia), includingthose with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates, vancomycin- resistant enterococcus infections, including cases with concurrent bacteraemia, and treatment of Clostridium d/ f/c//e-associated diarrhea (CDAD). ln another preferred embodiment, a compound of the invention, or a therapeuticallyacceptable salt thereof, is administered together with a compound or agent that removes orsubstantially removes or reduces the integrity of the cell wall of the bacterial agent. As anexample, the compound is selected from the group consisting of: ß lactams, fosfomycin,lysozyme, polymyxins and chelating agents such as ethylenediaminetetraacetic acid (EDTA).As an example, the agent is an immunological agent (such as an antibody or vaccine) thatreduces the integrity of the cell wall. ln one preferred embodiment, the compound, or atherapeutically acceptable salt thereof, is administered together with a compound thatremoves or substantially removes or weakens the integrity of the outer cell wall of a Gram- negative bacterial agent.

According to another aspect of the invention, there is provided an antibacterialpharmaceutical composition comprising a therapeutically effective amount of a compound ofFormula l, or a therapeutically acceptable salt thereof. Preferably, the composition is an antibacterial pharmaceutical composition. 12 According to another aspect of the invention, there is provided an antibacterial veterinarycomposition comprising a therapeutically effective amount of a compound of Formula I, or atherapeutically acceptable salt thereof. Preferably, the composition is an anti-bacterial veterinary composition, for topical or oral use.

The pharmaceutical composition may optionally include a pharmaceutically acceptableexcipient or carrier. The veterinary composition may optionally include a veterinary acceptable excipient or carrier. ln another embodiment, the pharmaceutical or veterinary composition comprises impurities,wherein the quantity of impurities as a percentage of the total Weight of the composition isselected from the group consisting of: less than 20% impurities (by total weight of thecomposition); less than 15% impurities; less than 10% impurities; less than 8% impurities;less than 5% impurities; less than 4% impurities; less than 3% impurities; less than 2%impurities; less than 1 % impurities; less than 0.5% impurities; less than 0.1 % impurities. lnone embodiment, the pharmaceutical or veterinary composition comprises microbialimpurities or secondary metabolites, wherein the quantity of microbial impurities as apercentage of the total Weight of the composition is selected from the group consisting of:less than 5%; less than 4%; less than 3%; less than 2%; less than 1 %; less than 0.5%; lessthan 0.1 %; less than 0.01 %; less than 0.001 %. ln one embodiment, the pharmaceutical orveterinary composition is sterile and stored in a sealed and sterile container. ln oneembodiment, the pharmaceutical or veterinary composition contains no detectable level of microbial contamination.

The pharmaceutical or veterinary composition of the invention may comprise a furtherantimicrobial agent. The further antimicrobial agent may be an antifungal agent orantibacterial agent. The method of treating or preventing a bacterial infection or colonisationin a subject, may also comprise the administration of a compound of the invention with a further antimicrobial agent.

The pharmaceutical or veterinary composition of the invention may comprise more than onecompound of the invention, such as a combination of compounds. The method of treating orpreventing a bacterial infection or colonisation in a subject may also comprise the administration of more than one compound of the invention. 13 ln one embodiment, the antifungal agent is selected from the group comprising, but notlimited to naturally occurring agents including Echinocandins (Anidulafungin, Caspofungin,Micafungin), Polyenes (Amphotericin B, Candicidin, Filipin, Fungichromin (Pentamycin),Hachimycin, Hamycin, Lucensomycin, Mepartricin, Natamycin, Nystatin, Pecilocin,Perimycin), and other naturally occurring antifungal agents including Griseofulvin,Oligomycins, Pyrrolnitrin, Siccanin, and Viridin. The antifungal agent may be a syntheticcompound selected from the group comprising, but not limited to Allylamines (Butenafine,Naftifine, Terbinafine) lmidazoles (Bifonazole, Butoconazole, Chlormidazole, Climbazole,Croconazole (Cloconazole), Clotrimazole, Eberconazole, Econazole, Enilconazole,Fenticonazole, Flutrimazole, Fosfluconazole, lsoconazole, Ketoconazole, Lanoconazole,Luliconazole, Miconazole, Neticonazole, Omoconazole, Oxiconazole Nitrate, Parconazole,Sertaconazole, Sulconazole, Tioconazole), Thiocarba mates (Liranaftate, Tolciclate,Tolindate, Tolnaftate), Triazoles (Fluconazole, lsavuconazole, ltraconazole, Posaconazole,Ravuconazole, Saperconazole, Terconazole, Voriconazole), and other synthetic agents suchas Acrisorcin, Amorolfine, Bromosalicylchloranilide (Bromochlorosalicylanilide), Buclosamide,Calcium Propionate, Chlorphenesin, Ciclopirox, Cloxyquin (Cloxiquine), Coparaffinate,Exalamide, Flucytosine, Haloprogin, Hexetidine, Loflucarban, Nifuratel, Nifuroxime,Piroctone, Potassium lodide, Propionic Acid, Pyrithione, Salicylanilide, SodiumParachlorobenzoate, Sodium Propionate, Sulbentine, Tenonitrozole, Triacetin, Trimetrexate, Undecylenic Acid (Undecenoic Acid), and Zinc Propionate.

The composition of the invention may comprise an antibiotic adjunct selected from the groupcomprising, but not limited to, ß-Lactamase lnhibitors (Avibactam, Clavulanic Acid,Sulbactam, Sultamicillin, Tazobactam), Renal Dipeptidase lnhibitors (Cilastatin), and Renal Protectant (Betamipron). ln one embodiment, the composition of the invention comprises a further antibiotic selectedfrom the group comprising, but not limited to, 2,4-DIAMINOPYRIMIDINES, including Baquiloprim, Brodimoprim, lclaprim, Ormetoprim,Pyrimethamine, Tetroxoprim, Trimethoprim; AMINOCOUMARINS, including Novobiocin; AMI NOCYCLITOLS, including Spectinomycin; AMINOGLYCOSIDES, including Amikacin, Apramycin, Arbekacin, Bekanamycin, Butirosin,Dibekacin, Dihydrostreptomycin, Etimicin, Fortimicins (Astromicin), Framycetin, Gentamicin,Hygromycin B, lsepamicin, Kanamycin, Micronomicin, Neomycin, Netilmicin, Paromomycin, Plazomicin, Ribostamycin, Sisomicin, Streptomycin, Tobramycin, Verdamicin; 14 AMINOMETHYLCYCLINES, including Omadacycline; AMPHENICOLS, including Azidamfenicol, Chloramphenicol, Florfenicol, Thiamphenicol;ANSAMYCINS, including Rifabutin, Rifamide, Rifampin (Rifampicin), Rifamycin, Rifapentine,Rifaximin; ANTISEPTIC AGENTS, including Acridine derivatives (including acriflavine, aminoacridine,ethacridine, proflavine), Bispyridines (including octenidine dihydrochloride), Brominatedsalicylanilides (including bromsalans), Chlorhexidine, Phenol derivatives (including thymoland triclosan), Quarternary ammonium compounds (including AlkyldimethylethylbenzyiAmmonium Chloride, benzalkonium chloride, cetylpyridinium chloride, benzethoniumchloride, cetrimonium); ANTITUBERCULAR AGENTS, including Cycloserine, Delamanid, Ethambutol, Ethionamide,lsoniazid (Ftivazide), Morinamide, p-Aminosalicylic Acid (PAS), Protionamide, Pyrazinamide,Terizidone, Thioacetazone, Tiocarlide; ARSENICALS, including Arsanilic Acid, Roxarsone; BACTERIOCINS, including Nisin, Brilacidin (PMX-30063); ß-LACTAIVI CARBACEPHEMS, including Loracarbef; ß-LACTAIVI CARBAPENEMS, including Biapenem, Doripenem, Ertapenem, Faropenem,lmipenem, Meropenem, Panipenem, Razupenem, Ritipenem, Sulopenem, Tebipenem,Tomopenem; ß-LACTAIVI CEPHALOSPORINS, including Cefacetrile, Cefaclor, Cefadroxil, Cefalexin,Cefaloglycin, Cefalonium, Cefaloridine, Cefalothin, Cefamandole, Cefapirin, Cefatrizine,Cefazaflur, Cefazedone, Cefazolin, Cefcapene, Cefdinir, Cefditoren, Cefepime, Cefetamet,Cefixime, Cefmenoxime, Cefodizime, Cefonicid, Cefoperazone, Ceforanide, Cefoselis,Cefotaxime, Cefotiam, Cefovecin, Cefozopran, Cefpimizole, Cefpiramide, Cefpirome,Cefpodoxime, Cefprozil, Cefquinome, Cefradine, Cefroxadine, Cefsulodin, Ceftaroline,Ceftazidime, Cefteram, Ceftezole, Ceftibuten, Ceftiofur, Ceftizoxime, Ceftobiprole,Ceftolozane, Ceftradine, Ceftrezole, Ceftriaxone, Ceftroxadine, Cefuroxime, Cefuzonam,Pivcefalexin; ß-LACTAIVI CEPHAMYCINS, including Cefbuperazone, Cefmetazole, Cefminox, Cefotetan,Cefoxitin; ß-LACTAIVI MONOBACTAMS, including Aztreonam, Carumonam, Tigemonam;ß- LACTAM OXACEPHEMS, including Flomoxef, Latamoxef, Moxalactam; ß-LACTAIVI PENICILLINS, including Amdinocillin (Mecillinam), Amoxicillin, Ampicillin,Apalcillin, Aspoxicillin, Azidocillin, Azlociliin, Bacampicillin, Carbenicillin, Carindacillin,Ciclacillin, Clemizole Penicillin, Clometocillin, Cloxacillin, Cyclacillin, Dicloxacillin, Epicillin,Fenbenicillin, Floxacillin (Flucloxacillin), Hetacillin, Lenampicillin, Mecillinam, Metampicillin,Methicillin Sodium, Mezlocillin, Nafcillin, Oxacillin, Penamecillin, Penethamate Hydriodide, Penicillin G, Penicillin G Benzathine, Penicillin G Procaine, Penicillin N, Penicillin O, PenicillinV, Phenethicillin Potassium, Piperacillin, Pivampicillin, Pivmecillinam, Propicillin, Quinacillin,Sulbenicillin, Sultamicillin, Talampicillin, Temocillin, Ticarcillin; BICYCLOMYCINS, including Bicozamycin; BORON CONTAINING ANTIBACTERIAL AGENTS, including AN3365(aminomethylbenzoxaboroles), GSK2251052 (leucyl-tRNA synthetase inhibitors); CYCLIC ESTERS, including Fosfomycin; EFFLUX PUMP INHIBITORS; FATTY ACID SYNTHESIS INHIBITORS (Fabl), AFN-1252, MUT056399, FAB-001FLUOROQUINOLONES, including Avarofloxacin, Balofloxacin, Besifloxacin, Chinfloxacin,Cinoxacin, Ciprofloxacin, Clinafloxacin, Danofloxacin, Delafloxacin, Difloxacin, Enoxacin,Enrofloxacin, Finafloxacin, Fleroxacin, Flumequine, Garenoxacin, Gatifloxacin, Gemifloxacin,Grepafloxacin, lbafloxacin, Levofloxacin, Lomefioxacin, Marbofloxacin, Miloxacin,Moxifloxacin, Nadifloxacin, Norfloxacin, Ofloxacin, Orbifloxacin, Pazufloxacin, Pefloxacin,Pradofloxacin, Prulifloxacin, Rosoxacin, Rufloxacin, Sarafloxacin, Sitafloxacin, Sparfloxacin,Temafloxacin, Tosufloxacin, Trovafloxacin, Zabofloxacin; FUSIDANES, including Fusidic Acid; GLYCOLIPODEPSIPEPTIDE, including Ramoplanin; GLYCOPEPTIDES, including Avoparcin, Dalbavancin, Norvancomycin, Oritavancin,Teicoplanin, Telavancin, Vancomycin,; GLYCOPHOSPHOLIPIDS, including Bambermycins (bambermycin, moenomycins,f|avophospho|ipo|); GLYCYLCYCLINES, including Tigecycline; HYBRIDS, Cadazolid (Oxazolidinone-quinolone), TD-1792 (glycopeptide-cephalosporin);LINCOSAMIDES, including Clindamycin, Lincomycin, Pirlimycin; LIPOPEPTIDES, including Daptomycin, Surotomycin; MACROLIDES, including Azithromycin, Carbomycin, Cethromycin, Clarithromycin,Dirithromycin, Erythromycin, Fidaxomicin, Flurithromycin, Gamithromycin, Josamycin,Kitasamycin, Leucomycin, Meleumycin, Midecamycins, Miokamycin, Mirosamycin,Oleandomycin, Primycin, Rokitamycin, Rosaramicin, Roxithromycin, Sedecamycin,Solithromycin, Spiramycin, Telithromycin, Terdecamycin, Tildipirosin, Tilmicosin,Troleandomycin, Tulathromycin, Tylosin, Tylvalosin; NITROFURANS, including Furaltadone, Furazidin, Furazolidone, Furazolium Chloride,Nifuratel, Nifurfoline, Nifuroxazide, Nifurpirinol, Nifurtoinol, Nifurzide, Nitrofural,Nitrofurantoin, Nitrofurazone; 16 NITROIMIDAZOLES, including Dimetridazole, Metronidazole, Ornidazole, Ronidazole,Secnidazole, Tinidazole; OLIGOSACCHARIDES, including Avilamycin, Everninomicin; OTHER ANTIBACTERIAL AGENTS, including Auriclosene, Chloroxine, Chlorquinaldol,Clioquinol, Clofoctol, Halquinol, Lotilibcin, Mandelic Acid, Methenamine (hexamine), Nitazole,Nitroxoline, Perchlozone, Taurolidine, Thenoic Acid, Xibornol; OXAZOLID1NONES, including Eperezolid, Linezolid, Posizolid, Radezolid, Sutezolid,Tedizolid (Torezolid); PEPTIDE DEFORMYLASE INHIBITORS, including GSK1322322; PEPTIDES, including Omiganan, Pexiganan; PLEUROMUTILINS, including Retapamulin, Tiamulin, Valnemulin; POLYETHER IONOPHORES, including Laidlomycin, Lasalocid, Maduramicin, Monensin,Narasin, Salinomycin, Semduramicin; POLYMYXINS, including Colistin, Polymyxin B; POLYPEPTIDES, including Amphomycin, Bacitracin, Capreomycin, Enduracidin, Enramycin,Enviomycin, Fusafungine, Gramicidin(s), lseganan, Magainins, Nosiheptide, Ristocetin,Thiostrepton, Tuberactinomycin, Tyrocidine, Tyrothricin, Viomycin; PSEUDOMONIC ACIDS, including Mupirocin; QUINOLONES, including Nalidixic Acid, Nemonoxacin, Oxolinic Acid, Ozenoxacin, PipemidicAcid, Piromidic Acid; QUINOXALINES, including Carbadox, Olaquindox; RIMINOFENAZINES, including Clofazimine; STATINS, including Atorvastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin,Pravastatin, Rosuvastatin, Simvastatin; STREPTOGRAMINS, including Dalfopristin, Flopristin, Linopnstin, Pristinamycin,Quinupristin, Virginiamycin; STREPTOTHRICINS, including Nourseothricin; SULFONAMIDES, including Acetyl Sulfamethoxypyrazine, Chloramine-B, Chloramine-T,Dichloramine T, Formosulfathiazole, Mafenide, N4-Sulfanilylsulfanilamide, Noprylsulfamide,N- Sulfanilyl-3,4-xylamide, Ormaosulfathiazole, Phthalylsulfacetamide, Phthalylsulfathiazole,Salazosulfadimidine, Succinylsulfathiazole, Sulfabenzamide, Sulfacarbamide, Sulfacetamide,Sulfachlorpyridazine, Sulfachrysoidine, Sulfaclozine, Sulfacytine, Sulfadiazine,Sulfadicramide, Sulfadimethoxine, Sulfadimidine, Sulfadoxine, Sulfaethidole, Sulfaguanidine,Sulfaguanole, Sulfalene, Sulfaloxic Acid, Sulfamerazine, Sulfameter, Sulfamethazine,Sulfamethizole, Sulfamethomidine, Sulfamethoxazole, Sulfamethoxypyridazine,Sulfamethylthiazole, Sulfametopyrazine, Sulfametrole, Sulfamidochrysoidine, 17 Sulfamonomethoxine, Sulfamoxole, Sulfanilamide, Sulfanilylurea, Sulfaperine,Sulfaphenazole, Sulfaproxyline, Sulfapyrazine, Sulfapyridine, Sulfaquinoxaline, Sulfathiazole,Sulfathiourea, Sulfatroxazole, Sulfisomidine, Sulfisoxazole (Sulfafurazole); SULFONES, including Acediasulfone, Dapsone, Glucosulfone Sodium, p-Sulfanilylbenzylamine, Succisulfone, Sulfanilic Acid, Sulfoxone Sodium, Thiazolsulfone;TETRACYCLINES, including Chlortetracycline, Clomocycline, Demeclocycline, Doxycycline,Eravacycline, Guamecycline, Lymecycline, Meclocycline, Methacycline, Minocycline,Oxytetracycline, Penimepicycline, Pipacycline, Rolitetracycline, Sarecycline, and Tetracycline.

The composition of the invention may further comprise an excipient selected from the groupcomprising, but not limited to, binders and compression aids, coatings and films, colouringagents diluents and vehicles disintegrants, emulsifying and solubilising agents, flavours andsweeteners, repellents, glidants and lubricants, plasticisers, preservatives, propellants, solvents, stabilisers, suspending agents and viscosity enhancers.

According to a further aspect of the invention, there is provided a medical device when used in a method of treating or preventing a bacterial infection in the subject.

According to further aspect of the invention, there is provided a medical device comprisingthe composition of the invention. The composition of the invention may be any slow release form, and/or in the form of a coating of the medical device.

The medical device may be in a form selected from the group comprising: an implant, a plaster, a bandage, and other dressing applied to a bacterial infection in a subject.

According to further aspect of the invention, there is provided a method of killing bacteria, themethod including the step of contacting the bacteria With a compound of the invention, or atherapeutically acceptable salt thereof. As discussed elsewhere in the present application,administration may e.g. be by creme, ointment, eye drops or by catheter to the bladder of the patient.

According to further aspect of the invention, there is provided the use of a compound of theinvention, or a therapeutically acceptable salt thereof, to kill bacteria, said use comprising thestep of contacting the bacteria with a compound of the invention, or a therapeutically acceptable salt thereof. 18 DESCRIPTION OF DRAWING Figure 1 shows the results of Example 2, and illustrates blood samples taken at relevanttimepoints over 48 hours, and the plasma concentration of the compound of Example 1determined by LC/MS/MS. lt appears from this graph that the compound according to the invention exhibits excellent dose dependent exposure. 19 DESCRIPTION OF EMBODIMENTS General Before describing the present invention in detail, it is to be understood that the invention isnot limited to particular exemplified methods or compositions disclosed herein. lt is also to beunderstood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

All publications referred to herein, including patents or patent applications, are incorporatedby reference in their entirety. However, applications that are mentioned herein are referred tosimply for the purpose of describing and disclosing the procedures, protocols, and reagentsreferred to in the publication which may have been used in connection with the invention.The citation of any publications referred to herein is not to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. ln addition, the carrying out of the present invention makes use of, unless othenNiseindicated, conventional microbiological techniques within the skill of the art. Such conventional techniques are known to the skilled Worker.

As used herein, and in the appended claims, the singular forms "a", "an", and "the" include the plural unless the context clearly indicates othenNise.

Unless othenNise indicated, all technical and scientific terms used herein have the samemeanings as commonly understood by one of ordinary skill in the art to which this inventionbelongs. Although any materials and methods similar to, or equivalent to, those describedherein may be used to carry out the present invention, the preferred materials and methods are herein described.

The invention described herein may include one or more ranges of values (e.g. size,concentration, dose etc). A range of values will be understood to include all values within therange, including the values defining the range, and values adjacent to the range that lead tothe same or substantially the same outcome as the values immediately adjacent to that value which define the boundary of the range.

The pharmaceutical or veterinary compositions of the invention may be administered in avariety of unit dosages depending on the method of administration, target site, physiological state of the patient, and other medicaments administered. For example, unit dosage form suitable for oral administration include solid dosage forms such as powder, tablets, pills, andcapsules, and liquid dosage forms, such as elixirs, syrups, solutions and suspensions. Theactive ingredients may also be administered parenterally in sterile liquid dosage forms.Gelatin capsules may contain the active ingredient and inactive ingredients such as powdercarriers, glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives,magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate, and thelike. Topical forms were discussed above and are included as an alternative in all aspects of the present invention.

The phrase "therapeutically effective amount" as used herein refers to an amount sufficientto inhibit bacterial growth associated with a bacterial infection or colonisation. That is,reference to the administration of the therapeutically effective amount of a compound ofFormula I according to the methods or compositions of the invention refers to a therapeuticeffect in which substantial bacteriocidal or bacteriostatic activity causes a substantialinhibition of bacterial infection. The term "therapeutically effective amount" as used herein,refers to a sufficient amount of the composition to provide the desired biological, therapeutic,and/or prophylactic result. The desired results include elimination of bacterial infection orcolonisation or reduction and/or alleviation of the signs, symptoms, or causes of a disease, orany other desired alteration of a biological system. An effective amount in any individual casemay be determined by one of ordinary skill in the art using routine experimentation. lnrelation to a pharmaceutical or veterinary composition, effective amounts can be dosagesthat are recommended in the modulation of a diseased state or signs or symptoms thereof.Effective amounts differ depending on the composition used and the route of administrationemployed. Effective amounts are routinely optimized taking into considerationpharmacokinetic and pharmacodynamic characteristics as well as various factors of aparticular patient, such as age, weight, gender, etc and the area affected by disease or disease causing microbes.

As referred to herein, the terms "treatment" or "treating" refers to the full or partial removal ofthe symptoms and signs of the condition as well as any trace or sign of the causing bacteria.For example, in the treatment of a bacterial infection or colonisation, the treatmentcompletely or partially removes the signs of the infection as well as any bacteria as such.Preferably in the treatment of infection, the treatment reduces or eliminates the infectingbacterial pathogen leading to microbial cure, and prevention of transmission of any seriousdevelopment of the infection. The term ”elimination” refers herein to the total removal of all signs and trace of an infection. 21 As referred to herein, the term "bacteria" refers to members of a large domain of prokaryoticmicroorganisms. Typically a few micrometres in length, bacteria have a number of shapes,ranging from spheres to rods and spirals and can be present as individual cells or present inlinear chains or clusters of variable numbers and shape. Preferably the terms "bacteria" andits adjective "bacterial" refer to bacteria such as the Gram-positive Staphylococcus spp,Streptocccus spp, Bacillus spp, Enferococcus spp, Listeria spp, and anaerobic bacteria; Theterms may refer to an antibiotic-sensitive strain or an antibiotic-resistant strain. ln a preferredembodiment, the terms refer to MRSA or MRSP. ln another preferred embodiment, the termsrefer to MDR Staphylococcus spp, Streptococcus spp, Enterococcus spp, Clostridiumdifficile. The term may also refer to Gram-negative bacteria such as Enterobaceriaceae spp,Klebsiella spp, Neisseria spp, Acinetobacter spp, Campylobacter spp, Salmonella spp, Shigella spp, Pseudomonas spp.

Referred to herein, the term "methicillin-resistant bacteria" (such as methicillin- resistantStaphylococcus) refers a bacteria isolate that demonstrates resistance at any dose to all ß-lactams including penicillins, carbapenems and first to fourth generation cephalosporins, butnot to the fifth generation anti-MRSAcephalosporins (for example ceftaroline). Multidrug-resistant (MDR) is defined as acquired non-susceptibility to at least one agent in three ormore antimicrobial categories, extensively drug-resistant (XDR) is defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e.bacterial isolates remain susceptible to only one or tvvo categories) and pandrug-resistant(PDR) is defined as non- susceptibility to all agents in all antimicrobial categories currently available.

An example of susceptible, MDR, XDR and PDR bacteria includes the following. Wiid type,antibacterial unexposed isolates of Staphylococcus aureus that are likely to be susceptible toall of the following antibacterial categories (and agents); aminoglycosides (for examplegentamicin); ansamycins (for example rifampicin); anti-MRSA cephalosporins (for exampleceftaroline); anti-staphylococcal ß-lactams (or cephamycins) (for example oxacillin orcefoxitin); carbapenems (for example ertapenem, imipenem, meropenem or doripenem);non-extended spectrum cephalosporins; 1 st and 2nd generation cephalosporins (forexample cefazolin or cefuroxime); extended-spectrum cephalosporins; 3rd and 4thgeneration cephalosporins (for example cefotaxime or ceftriaxone); cephamycins (forexample cefoxitin or cefotetan); fluoroquinolones (for example ciprofloxacin or moxifloxacin); folate pathway inhibitors (for example trimethoprim-sulphamethoxazole); fucidanes (for 22 example fusidic acid); glycopeptides (for example vancomycin, teicoplanin or telavancin);glycylcyclines (for example tigecycline); lincosamides (for example clindamycin); lipopeptides(for example daptomycin); macrolides (for example erythromycin); oxazolidinones (forexample linezolid or tedizolid); phenicols (for example chloramphenicol); phosphonic acids(for example fosfomycin); streptogramins (for example quinupristin-dalfopristin; andtetracyclines (for example tetracycline, doxycycline or minocycline). lsolates that are non-susceptible to more than one agent in more than three antimicrobial categories are classifiedas MDR (all MRSA, for example, meet the definition of MDR). lsolates that are non- susceptible to more than one agent in all but one or two antimicrobial categories are classified as XDR. lsolates that are non-susceptible to all listed antibacterial agents are PDR.

The use of compounds according to the invention, as defined by Formula I, avoids the use of other antibiotics and thus resistance development to such antibiotics.

Pharmaceutically and veterinary acceptable salts include salts which retain the biologicaleffectiveness and properties of the compounds of the present disclosure and which are notbiologically or othenNise undesirable. ln many cases, the compounds disclosed herein arecapable of forming acid and/or base salts by virtue of the presence of amino and/or carboxylgroups or groups similar thereto. Acceptable base addition salts can be prepared frominorganic and organic bases. Salts derived from inorganic bases, include by way of exampleonly, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derivedfrom organic bases include, but are not limited to, salts of primary, secondary and tertiaryamines, such as by way of example only, alkyl amines, dialkyl amines, trialkyl amines,substituted alkyl amines, di(subsrituted alkyl) amines, tri(substituted alkyl) amines, alkenylamines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substitutedalkenyl) amines, tri (substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines,tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amines,trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines,tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amines,trisubstituted cycloalkenyl amines, aryl amines, diary' amines, triaryl amines, heteroarylamines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclicamines, triheterocyclic amines, mixed di- and tri-amines where at least two of thesubstituents on the amine are different and are selected from the group consisting of alkyl,substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines 23 Where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group.

Pharmaceutically and veterinary acceptable acid addition salts may be prepared frominorganic and organic acids. The inorganic acids that can be used include, by way ofexample only, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid,and the like. The organic acids that can be used include, by way of example only, acetic acid,propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid,maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

The pharmaceutically or veterinary acceptable salts of the compounds useful in the presentdisclosure can be synthesized from the parent compound, which contains a basic or acidicmoiety, by conventional chemical methods. Generally, such salts can be prepared byreacting the free acid or base forms of these compounds with a stoichiometric amount of theappropriate base or acid in water or in an organic solvent, or in a mixture of the two;generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrileare preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences. 17thed., Mack Publishing Company, Easton, Pa. (1985), p. 1418, the disclosure of Which ishereby incorporated by reference. Examples of such acceptable salts are the iodide, acetate,phenyl acetate, trifluoroacetate, acryl ate, ascorbate, benzoate, chlorobenzoate,dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methyl benzoate, o-acetoxybenzoate,naphthalene-2- benzoate, bromide, isobutyrate, phenylbutyrate, y-hydroxybutyrate, ß-hydroxybutyrate, butyne- l,4-dioate, hexyne-l,4-dioate, hexyne- 1 ,6-dioate, caproate,caprylate, chloride, cinnamate, citrate, decanoate, formate, fumarate, glycollate, heptanoate,hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate,nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate,monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate,propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate,bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate,chlorobenzenesulfonate, propanesulfonate, ethanesulfonate, 2- hydroxyethanesulfonate,merhanesulfonate, naphthalene-l-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.

The present invention also includes isotope-labelled compounds of formula I or any subgroup of formula l, wherein one or more of the atoms is replaced by an isotope of that atom, i.e. an 24 atom having the same atomic number as, but an atomic mass different from, the one(s)typically found in nature. Examples of isotopes that may be incorporated into the compoundsof formula I or any subgroup of formula I, include but are not limited to isotopes of hydrogen,such as 2H and 3H (also denoted D for deuterium and T for tritium, respectively), carbon,such as ”C, ”C and MC, nitrogen, such as ”N and ”N, oxygen, such as 150, ”O and ”O,phosphorus, such as “P and 32P, sulfur, such as 358, fluorine, such as ”F, chlorine, such as36Cl, bromine such as 75Br, 76Br, "Br and 82Br, and iodine, such as ”3l, mi, ”öl and ”1l. Thechoice of isotope included in an isotope-labelled compound will depend on the specificapplication of that compound. For example, for drug or substrate tissue distribution assays,compounds wherein a radioactive isotope such as 3H or ”C is incorporated will generally bemost useful. For radio-imaging applications, for example positron emission tomography(PET) a positron emitting isotope such as ”C, ”F, ”N or ”O will be useful. The incorporationof a heavier isotope, such as deuterium, i.e. 2H, may provide greater metabolic stability to acompound of formula I or any subgroup of formula I, which may result in, for example, an increased in vivo half-life of the compound or reduced dosage requirements. lsotope-labelled compounds of formula I or any subgroup of formula I can be prepared byprocesses analogous to those described in the Schemes and/or Examples herein below byusing the appropriate isotope-labelled reagent or starting material instead of thecorresponding non-isotope-labelled reagent or starting material, or by conventional techniques known to those skilled in the art.

The compounds of the invention can have one or several chiral centers and may exist and beisolated in optically active and racemic forms. Some compounds may exhibit polymorphism.lt is to be understood that any racemic, optically active, diastereomeric, polymorphic orstereoisomeric form or mixtures thereof, of a compound provided herein is within the scopeof this invention. The absolute configuration of such compounds can be determined usingmethods known in the art such as, for example, X-ray diffraction or NMR and/or implicationfrom starting materials of known stereochemistry and/or stereoselective synthesis methods.Pharmaceutical compositions in accordance with the invention will preferably comprise substantially stereoisomerically pure preparations of the indicated stereoisomer.

Pure stereoisomeric forms of the compounds and intermediates as mentioned herein aredefined as isomers substantially free of other enantiomeric or diastereomeric forms of thesame basic molecular structure of said compounds or intermediates. ln particular, the term “stereoisomerically pure” concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e. minimum 90% of one isomer and maximum 10% of the otherpossible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and noneof the other), more in particular, compounds or intermediates having a stereoisomeric excessof 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to100% and most in particular having a stereoisomeric excess of 97% up to 100%. The terms“enantiomerically pure” and “diastereomerically pure” should be understood in a similar way,but then having regard to the enantiomeric excess, and the diastereomeric excess, respectively, of the mixture in question.

Pure stereoisomeric forms of the compounds and intermediates of this invention may beobtained by using procedures well known in the art. For instance, enantiomers may beseparated from each other by resolution of the racemic mixture, i.e. formation of adiastereomeric salt effected by reaction with an optically active acid or base followed byselective crystallization of the formed diastereomeric salt. Examples of such acids are tartaricacid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid. Alternatively,enantiomers may be separated by chromatographic techniques using chiral stationaryphases. Pure stereochemically isomeric forms may also be obtained by synthesis fromstereochemically pure forms of the appropriate starting materials, provided that the reactionoccurs stereospecifically, by chiral synthesis or by utilisation of a chiral auxiliary. lf a specificstereoisomer is desired, the preparation of that compound is preferably performed usingstereospecific methods. These methods will advantageously employ enantiomerically pure starting materials.

Diastereomeric racemates of the compounds of the invention can be separated byconventional methods. Appropriate physical separation methods that may advantageously beemployed are, for example, selective crystallization and chromatography, e.g. column ch romatography.

The terms and expressions used herein throughout the abstract, specification and claimsshall be interpreted as defined below unless othenNise indicated. The meaning of each termis independent at each occurrence. These definitions apply regardless of whether a term isused by itself or in combination with other terms, unless otherwise indicated. A term orexpression used herein which is not explicitly defined, shall be interpreted as having itsordinary meaning used in the art. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. lf a chemical compound is 26 referred to using both a chemical structure and a chemical name and an ambiguity exists between the structure and the name, the structure predominates.

"Cm-C,,alkyl" on its own or in composite expressions such as Cm-Cnhaloalkyl, Cm-Cnalkylcarbonyl, Cm-Cnalkylamine, etc. represents a straight or branched aliphatichydrocarbon radica| having the number of carbon atoms designated, e.g. C1-C4alkyl meansan alkyl radica| having from 1 to 4 carbon atoms. C1-C6alkyl has a corresponding meaning,including also all straight and branched chain isomers of pentyl and hexyl. Preferred alkylradicals for use in the present invention are C1-C6alkyl, including methyl, ethyl, n-propyl,isopropyl, n-butyl, isobutyl, sec-buty, tert-butyl, n-pentyl and n-hexyl, especially C1-C4alkylsuch as methyl, ethyl, n-propyl, isopropyl, terf-butyl, n-butyl and isobutyl. Methyl andisopropyl are typically preferred. An alkyl group may be unsubstituted or substituted by oneor more substituents which may be the same or different, each substituent beingindependently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl,cyano, hydroxy, Cm-Cnalkoxy, -O-aryl, -Cm-CnalkoxyCm-Cnalkyl, Cm-Cnalkylthio, -NH2, -NH(Cm-Cnalkyl), -N(Cm-C,,alkyl)2, -NH(cycloalkyl), -OC(O)alkyl, -O-C(O)aryl, -O-C(O)cycloalkyl, -C(O)OH and -C(O)OCm-C,,alkyl. lt is generally preferred that the alkyl group is unsubstituted, unless othenNise indicated.

"Cz-Cnalkenyl" represents a straight or branched aliphatic hydrocarbon radica| containing atleast one carbon-carbon double bond and having the number of carbon atoms designated,e.g. C2-C4alkenyl means an alkenyl radica| having from 2 to 4 carbon atoms; C2-C6alkenylmeans an alkenyl radica| having from 2 to 6 carbon atoms. Non-limiting alkenyl groupsinclude ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl and hexenyl. An alkenylgroup may be unsubstituted or substituted by one or more substituents which may be thesame or different, each substituent being independently selected from the group consisting ofhalo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, -O-aryl, alkoxyalkyl, alkylthio, -NH2, -NH(Cm-C,,alkyl), -N(Cm-C,,alkyl)2, -NH(C3-C,,cycloalkyl), -OC(O)Cm-C,,alkyl, -O-C(O)aryl,-O-C(O)C3-C,,cycloalkyl, -C(O)OH and -C(O)OCm-C,,alkyl. lt is generally preferred that the alkenyl group is unsubstituted, unless othenNise indicated.

"Cz-Cnalkynyl" represents a straight or branched aliphatic hydrocarbon radica| containing atleast one carbon-carbon triple bond and having the number of carbon atoms designated, e.g.C2-C4alkynyl means an alkynyl radica| having from 2 to 4 carbon atoms; C2-C6alkynyl meansan alkynyl radica| having from 2 to 6 carbon atoms. Non-limiting alkenyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl pentynyl and hexynyl. An alkynyl group may 27 be unsubstituted or substituted by one or more substituents which may be the same ordifferent, each substituent being independently selected from the group consisting of halo,Cz-Cnalkenyl, Cz-Cnalkynyl, aryl, Cg-Cncycloalkyl, cyano, hydroxy, Cm-Cnalkoxy, -O-aryl, -Cm-CnalkoxyCm-Cnalkyl, Cm-Cnalkylthio, -NH2, -NH(Cm-C,.alkyl), -N(Cm-C,.alkyl)2, -NH(C3-Cncycloalkyl), -O-C(O)-Cm-C,.alkyl, -O-C(O)ary|, -OC(O) Cg-Cncycloalkyl, -C(O)OH and -C(O)OCm-C,.alkyl. lt is generally preferred that the alkynyl group is unsubstituted, unless otherwise indicated.

The term “Cm-Cnhaloalkyl” as used herein represents Cm-Cnalkyl wherein at least one C atomis substituted With a halogen (e.g. the Cm-Cnhaloalkyl group may contain one to threehalogen atoms), preferably chloro or fluoro. Typical haloalkyl groups are C1-C2haloalkyl, inwhich halo suitably represents fluoro. Exemplary haloalkyl groups include fluoromethyl, difluromethyl and trifluoromethyl.

The term “Cm-Cnhydroxyalkyl” as used herein represents Cm-Cnalkyl wherein at least one Catom is substituted with one hydroxy group. Typical Cm-Cnhydroxyalkyl groups are Cm-Cnalkylwherein one C atom is substituted with one hydroxy group. Exemplary hydroxyalkyl groups include hydroxymethyl and hydroxyethyl.

The term "Me" means methyl, and "MeO" means methoxy.

The term “Cm-Cnalkylcarbonyl” represents a radical of the formula Cm-CnalkylC(=O)- whereinthe Cm-Cnalkyl moiety is as defined above. Typically, “Cm-Cnalkylcarbonyl” is C1-C6alkylC(=O)-.

"Cm-Cnalkoxy" represents a radical Cm-Cnalkyl-O- wherein Cm-Cnalkyl is as defined above. Ofparticular interest is C1-C4alkoxy which includes methoxy, ethoxy, n-propoxy, isopropoxy,tert-butoxy, n-butoxy and isobutoxy. Methoxy and isopropoxy are typically preferred. C1-Cßalkoxy has a corresponding meaning, expanded to include all straight and branched chain isomers of pentoxy and hexoxy.

The term ”halo” represents a halogen radical such as fluoro, chloro, bromo or iodo. Typically, halo groups are chloro and especially fluoro.

The term “Cg-Cncycloalkyl” represents a cyclic monovalent alkyl radical having the number of carbon atoms indicated, e.g. C3-C7cycloalkyl means a cyclic monovalent alkyl radical having 28 from 3 to 7 carbon atoms. Preferred cycloalkyl radicals for use in the present invention areC3-C4alkyl i.e. cyclopropyl and cyclobutyl. A cycloalkyl group may be unsubstituted orsubstituted by one or more substituents which may be the same or different, each substituentbeing independently selected from the group consisting of halo, Cz-Cnalkenyl, Cz-Cnalkynyl,aryl, cycloalkyl, cyano, hydroxy, Cm-Cnalkoxy, aryloxy, Cm-CnalkoxyCm-Cnalkyl, Cm-Cnalkylthio, -NH2, -NH(Cm-C,,alkyl), -N(Cm-C,,alkyl)2, -NH(cyc|oa|ky|), -O-C(O)Cm-C,,alkyl, -O-C(O)aryl, -O-C(O)C3-C,,cycloalkyl, -C(O)OH and -C(O)Oa|ky|. lt is generally preferred that the cycloalkyl group is unsubstituted, unless othenNise indicated.

The term “Cg-Cncycloalkenyl” represents a cyclic monovalent alkenyl radical having thenumber of carbon atoms indicated, e.g. C3-C7cycloalkenyl means a cyclic monovalent alkylradical having from 3 to 7 carbon atoms, and including at least one unsaturated bond,typically one such bond. Preferred cycloalkenyl radicals for use in the present invention areC5-C6alkyl i.e. cyclopropenyl and cyclohexenyl. A cycloalkyl group may be unsubstituted orsubstituted by one or more substituents which may be the same or different, each substituentbeing independently selected from the group consisting of halo, alkenyl, alkynyl, aryl,cycloalkyl, cyano, hydroxy, alkoxy, aryloxy, alkoxyalkyl, alkylthio, -NH2, -NH(Cm-C,,alkyl), -N(Cm-C,,alkyl)2, -NH(C3-C,,cycloalkyl), -O-C(O)Cm-C,,alkyl, -O-C(O)aryl, -O-C(O)C3-Cncycloalkyl, -C(O)OH and -C(O)OCm-C,,alkyl wherein Cm-Cnalkyl, Cg-Cncycloalkyl and arylare as defined above. lt is generally preferred that the cycloalkyl group is unsubstituted, unless othenNise indicated.The term "amino" represents NH2.

Compounds of the invention can be prepared by the methods depicted in the schemes belowand as detailed in the experimental descriptions. Starting materials and reagents used in thepreparation of the compounds of the invention are available from commercial suppliers suchas Aldrich Chemical Co., Bachem or Sigma, or they are prepared by methods known in theart following literature procedures. The schemes below are merely illustrative of somemethods by which the compounds of the invention can be prepared, and various modifications to these schemes can be made and will be obvious to one skilled in the art.

A general route to compounds of the invention wherein Rs is a bond with the adjacent carbon atom, thus providing a keto group, and R4 is H is illustrated in Scheme 1. o0 0 1.NaH OH O OM 2.Bu|_i , 1.0H' 00/ m* R, o ms.Rc|-|o 2.|-|+ R1 O18 1b 1co o oR2coc| o R2 4-pyrroiidinopyridine O R2á» l t iDBU Rt o o A Rt oH1d 1eSchemel Reaction of methyl acetoacetate (1a) with an aldehyde R1CHO under basic conditions suchas in the presence of sodium hydride and butyl lithium or similar provides the ö-hydroxy-ß-keto ester (1 b). The reaction is typically performed under anhydrous conditions in a solventlike THF or similar at a temperature below 5 °C, such as between 0 and 5 °C. Cyclisation ofthe afforded hydroxy compound effected by treatment with a base such as sodium hydroxideor similar followed by acidic treatment provides the pyran derivative (1c). The O-substituentis then introduced by reaction with a desired acyl chloride RZCOCI in the presence of a basesuch as DBU or similar, thus providing the ester derivative (1d). Treatment finally with a baselike pyrrolidinopyridine or similar at an elevated temperature, such as between 100 °C and150 °C, preferably around 130 °C, effects the rearrangement and provides the desired compound of formula l.

Compounds of the invention wherein Rs is a bond with the adjacent carbon atom, thusproviding a keto group, and R4 is optionally substituted C1-C6alkyl, Cg-Cßcycloalkyl or C3-C6cycloalkylC1-C3alkyl are obtained by alkylation of the hydroxy group of compound 1ewhereas compounds wherein R4 is an ester or an amino acid ester, i.e. C(O)R5 orC(O)CHR7NH2 respectively are achieved by acylation of the hydroxy group. These methods are generally illustrated in Scheme 2.

R4' is optionally substituted crceaikyi,C3-C6cycloalkyl or C3-C6cycloalkylC1-C3alkyl, X is a leaving group or OH Sche e 2 Alkylation of the hydroxy group of compound 1e effected by reaction with an alkylating agentlike an dialkyl sulphate, an alkyl sulfonate such as a triflate, tosylate or mesylate or an alkylhalide of the desired alkyl group in the presence of a base such as sodium hydride orpotassium carbonate or similar provides the alkylated derivative 2a. Alternatively, the groupR” may be introduced by reaction with the appropriate alcohol Rw-OH in the presence of anacid like p-toluene sulfonic acid or equivalent typically at elevated temperature, or by usingMitsunobu conditions, i.e. in the presence of an azodicarboxylate such as DIAD or equivalentand triphenylphosphine.

Compounds of the invention wherein OR4 is an ester group (2b), i.e. R4 is a group of formulaC(O)R5 are obtained by acylation of alcohol 1e with an acylating agent such as an alkylanhydride in the presence of pyridine, or an acid chloride or the like, whereas compoundswherein OR4 is an amino acid ester group (2c), i.e. R4 is a group of formula C(O)CHR7 areobtained by reaction of the alcohol (1e) with an amino acid, optionally N-protected with asuitable N-protecting group such as a Boc, CBz or Fmoc group, in the presence of a suitable peptide coupling reagent such as EDAC or the like.

Compounds of the invention wherein Rs is H are obtained by reduction of the exocyclic ketofunction using reduction conditions such sodium borohydride in the presence of cerium chloride in a solvent like THF or MeOH or similar, as illustrated in Scheme 3.

O O O OHQ R2 Reduction Q R2I H IRt oR4' Rt oR42a 3 31 A route to compounds of the invention wherein Rs is optionally substituted C1-C6alkyl, C3-Cßcycloalkyl or Cg-CßcycloalkylC1-C3alkyl are obtained by alkylation of the hydroxy group ofcompound 3 whereas compounds wherein Rs is an ester or an amino acid ester, i.e. C(O)Rsor C(O)CHR7NH2 respectively are obtained by acylation of the hydroxy group. These routesare depicted in Scheme 4.O OH Rs' O O Rs' and R4' are each independently optionallysubstituted C1-C6alkyl, C3-C6cycloalkyl or o R2Ri oR4' Fväfl cycscycioaikyic,-c3aikyi 3 4a X is a leaving group or OH O | Rz R3'_X O Rfßskcl HOJKKPQNH OO Rv O OÄKKNHZii) N-deprot. R? o | i» o | R2 R1 OR4 R1 OR44b 4cScheme í Alkylation of the hydroxy group of compound 3 effected by reaction with an alkylating agentlike an dialkyl sulphate, an a|ky| sulfonate such as a triflate, tosy|ate or mesylate or an a|ky|halide of the desired a|ky| group in the presence of a base such as sodium hydride orpotassium carbonate or similar provides the alkylated derivative 4a. Alternatively, the groupRs' may be introduced by reaction with the appropriate alcohol Rs-OH in the presence of anacid like p-toluene sulfonic acid or equivalent typically at elevated temperature.Compounds of the invention wherein ORs is an ester group, i.e. Rs is a group of formulaC(O)Rs are obtained by acylation of alcohol 3 with an acylating agent such as an a|ky|anhydride in the presence of pyridine, or an acid chloride or the like, whereas compoundswherein ORs is an amino acid ester group (4c), i.e. Rs is a group of formula C(O)CHR7NH2are obtained by reaction of the alcohol 3 with an amino acid, which is optionally N-protectedwith a suitable N-protecting group such as a Boc, CBz or Fmoc group, in the presence of a suitable peptide coupling reagent such as EDAC or the like.

To obtain compounds of formula I wherein R4 is H, and Rs together with the oxygen atom towhich it is attached form an ether or acyloxy moiety, a protecting strategy as illustrated in Scheme 5 can be used.

/R3IO Oi R~°>Lxë» O Rzii) Pg1 removal |Rl oH ikf i) o o o RSRl oH n) pg removai ii) Pgl removal Rl oHSe sd Ra' is optionally substituted C1-C6alkyl, C3-C6cycloalkyl or C3-C6cycloalkylC1-C3alkyl, X is a leaving group or OHchefi ä Protection of the hydroxy group of compound 1e as for instance an ether such as a THPether or a trityl ether or the like or as a silyl ether such as tert.butyl dimethylsilyl or tert.butyldiphenylsilyl or similar provides protected derivative 5a. Reduction of the keto group to analcohol can then be effected using e.g. sodium borohydride in the presence of ceriumchloride in a solvent like THF or MeOH or similar conditions provides the exocyclic alcohol5b. Alkylation or acylation using the desired alkylating or acylating agent respectively usingconditions as described above followed by removal of the protecting group(s), then provides the O-substituted compounds 5c, 5d and 5e.

The pharmaceutical or veterinary compositions of the invention may be formulated inconventional manner, together with other pharmaceutically acceptable excipients if desired,into forms suitable for oral, parenteral, or topical administration. The modes of administrationmay include parenteral, for example, intramuscular, subcutaneous and intravenousadministration, oral administration, topical administration and direct administration to sites ofinfection such as intraocular, intraaural, intrauterine, intranasal, intramammary, intraperitoneal, intralesional, etc.

The pharmaceutical or veterinary compositions of the invention may be formulated for oraladministration. Traditional inactive ingredients may be added to provide desirable colour,taste, stability, buffering capacity, dispersion, or other known desirable features. Examplesinclude red iron oxide, silica gel, sodium laurel sulphate, titanium dioxide, edible white ink,and the like. Conventional diluents may be used to make compressed tablets. Both tabletsand capsules may be manufactured as sustained-release compositions for the continualrelease of medication over a period of time. Compressed tablets may be in the form of sugar coated or film coated tablets, or enteric-coated tablets for selective disintegration in the 33 gastrointestinal tract. Liquid dosage forms for oral administration may contain colouringand/or flavouring to increase patient compliance. As an example, the oral formulationcomprising compounds of the invention may be a tablet comprising any one, or acombination of, the following excipients: calcium hydrogen phosphate dehydrate, microcrystalline cellulose, lactose, hydroxypropyl methyl cellulose, and talc.

The compositions described herein may be in the form of a liquid formulation. Examples ofpreferred liquid compositions include solutions, emulsions, injection solutions, solutionscontained in capsules. The liquid formulation may comprise a solution that includes atherapeutic agent dissolved in a solvent. Generally, any solvent that has the desired effectmay be used in which the therapeutic agent dissolves and which can be administered to asubject. Generally, any concentration of therapeutic agent that has the desired effect can beused. The formulation in some variations is a solution which is unsaturated, a saturated or asupersaturated solution. The solvent may be a pure solvent or may be a mixture of liquidsolvent components. ln some variations the solution formed is an in situ gelling formulation.Solvents and types of solutions that may be used are well known to those versed in such drug delivery technologies.

The composition described herein may be in the form of a liquid suspension. The liquidsuspensions may be prepared according to standard procedures known in the art. Examplesof liquid suspensions include micro-emulsions, the formation of complexing compounds, andstabilising suspensions. The liquid suspension may be in undiluted or concentrated form.Liquid suspensions for oral use may contain suitable preservatives, antioxidants, and otherexcipients known in the art functioning as one or more of dispersion agents, suspendingagents, thickening agents, emulsifying agents, wetting agents, solubilising agents, stabilisingagents, flavouring and sweetening agents, colouring agents, and the like. The liquid suspension may contain glycerol and water.

The composition described herein may be in the form of an oral paste. The oral paste may be prepared according to standard procedures known in the art.

The composition described herein may be in the form of a liquid formulation for injection,such as intra-muscular injection, and prepared using methods known in the art. For example, the liquid formulation may contain polyvinylpyrrolidone K30 and water. 34 The composition described herein may be in the form of topical preparations. The topicalpreparation may be in the form of a lotion or a cream, prepared using methods known in theart. For example, a lotion may be formulated with an aqueous or oily base and may includeone or more excipients known in the art, functioning as viscosity enhancers, emulsifyingagents, fragrances or perfumes, preservative agents, chelating agents, pH modifiers,antioxidants, and the like. For example, the topical formulation comprising one or morecompounds of the invention may be a gel comprising anyone, or a combination of, thefollowing excipients: PEG 8000, PEG 4000, PEG 200, glycerol, propylene glycol. Thecompound of formula I may further be formulated into a solid dispersion using SoluPlus(BASF, http://wvvw.soluplus.com) and formulated with any one, or a combination of, the following excipients: PEG 8000, PEG 4000, PEG 200, glycerol, and propylene glycol.

For aerosol administration, the composition of the invention is provided in a finely dividedform together with a non-toxic surfactant and a propellant. The surfactant is preferably soluble in the propellant. Such surfactants may include esters or partial esters of fatty acids.

The compositions of the invention may alternatively be formulated for delivery by injection.As an example, the compound is delivered by injection by any one of the following routes: intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous.

The compositions of the invention may alternatively be formulated using nanotechnologydrug delivery techniques such as those known in the art. Nanotechnology- based drugdelivery systems have the advantage of improving bioavailability, patient compliance and reducing side effects.

The formulation of the composition of the invention can include the preparation ofnanoparticles in the form of nanosuspensions or nanoemulsions, based on compoundsolubility. Nanosuspensions are dispersions of nanosized drug particles prepared by bottom-up or top- down technology and stabilised with suitable excipients. This approach may beapplied to the compounds of the invention which can have poor aqueous and lipid solubility,in order to enhance saturation solubility and improve dissolution characteristics. An exampleof this technique is set out in Sharma and Garg (2010) (Pure drug and polymer-basednanotechnologies for the improved solubility, stability, bioavailability, and targeting of anti-HIV drugs. Advanced Drug Delivery Reviews, 62: p. 491-502). Saturation solubility will beunderstood to be a compound-specific constant that depends on temperature, properties of the dissolution medium, and particle size (<1 -2 uni).

The composition of the invention may be provided in the form of a nanosuspension. Fornanosuspensions, the increase in the surface area may lead to an increase in saturationsolubility. Nanosuspensions are colloidal drug delivery systems, consisting of particles below1 pin. Compositions of the invention may be in the form of nanosuspensions includingnanocrystalline suspensions, solid lipid nanoparticles (SLNs), polymeric nanoparticles,nanocapsules, polymeric micelles and dendrimers. Nanosuspensions may be prepared usinga top-down approach where larger particles may be reduced to nanometre dimensions by avariety of techniques known in the art including wet-milling and high-pressurehomogenisation. Alternatively, nanosuspensions may be prepared using a bottom-up technique where controlled precipitation of particles may be carried out from solution.

The composition of the invention may be provided in the form of a nanoemulsion.Nanoemulsions are typically clear oil-in-water or water-in-oil biphasic systems, with a dropletsize in the range of 100-500 nm, and with compounds of interest present in the hydrophobicphase. The preparation of nanoemulsions may improve the solubility of the compounds ofthe invention described herein, leading to better bioavailability. Nanosized suspensions mayinclude agents for electrostatic or steric stabilisation such as polymers and surfactants.Compositions in the form of SLNs may comprise biodegradable lipids such as triglycerides,steroids, waxes and emulsifiers such as soybean lecithin, egg lecithin, and poloxamers. Thepreparation of a SLN preparation may involve dissolving/dispersing drug in melted lipidfollowed by hot or cold homogenisation. lf hot homogenisation is used, the melted lipidicphase may be dispersed in an aqueous phase and an emulsion prepared. This may besolidified by cooling to achieve SLNs. lf cold homogenisation is used, the lipidic phase maybe solidified in liquid nitrogen and ground to micron size. The resulting powder may be subjected to high-pressure homogenisation in an aqueous surfactant solution.

The Compounds of Formula I as described herein may be dissolved in oils/liquid lipids andstabilised into an emulsion formulation. Nanoemulsions may be prepared using highland low-energy droplet reduction techniques. High-energy methods may include high-pressurehomogenisation, ultrasonication and microfluidisation. lf the low-energy method is used,solvent diffusion and phase inversion will generate a spontaneous nanoemulsion. Lipidsused in nanoemulsions may be selected from the group comprising triglycerides, soybean oil,safflower oil, and sesame oil. Other components such as emulsifiers, antioxidants, pH modifiers and preservatives may also be added. 36 The composition may be in the form of a controlled-release formulation and may include adegradable or non-degradable polymer, hydrogel, organogel, or other physical construct thatmodifies the release of the compound. lt is understood that such formulations may includeadditional inactive ingredients that are added to provide desirable colour, stability, bufferingcapacity, dispersion, or other known desirable features. Such formulations may furtherinclude liposomes, such as emulsions, foams, micelles, insoluble monolayers, liquid crystals,phospholipid dispersions, lamellar layers and the like. Liposomes for use in the inventionmay be formed from standard vesicle-forming lipids, generally including neutral andnegatively charged phospholipids and a sterol, such as cholesterol. 100205] Theformulations of the invention may have the advantage of increased solubility and/or stabilityof the compounds, particularly for those formulations prepared using nanotechnologytechniques. Such increased stability and/or stability of the compounds of Formula I mayimprove bioavailability and enhance drug exposure for oral and/or parenteral dosage forms.Throughout this specification, unless the context requires othenNise, the word "comprise" orvariations such as "comprises" or "comprising", will be understood to imply the inclusion of astated integer or group of integers but not the exclusion of any other integer or group of integers. ln addition to the definitions above, the following abbreviations are used in the examples andsynthetic schemes below. lf an abbreviation used herein is not defined, it has its generally accepted meaning.

DBU 1,8-Diazabicyclo[5.4.0]undec-7-eneDCM Dichloromethane DMF N,N-Dimethylformamide ES Electrospray Et3N Triethylamine EtOAc Ethyl acetate EtOH Ethanol LC Liquid chromatography HOAc Acetic acid HPLC High performance liquid chromatographyMeCN Acetonitrile MeOH Methanol MIC Minimum inhibition concentration MS Mass spectrometry 37 PBS Phosphate buffered salinePg Protecting group Ph Phenyl THF Tetrahydrofuran TFA Trifluoroacetic acid VPB Vegetable Peptone Broth SYNTHESIS EXAMPLES Example 1 1. NaH O 2. BuLi 1. OH' e» / i* M s. cgci-io OH O 2_ HC| fåO/ Step a G9 O Step b O O G918 1bO Ä MO 4-pyrrolidino-Cl DBUa» pyridine, O OHStepdO O G9 O O G91c 1dStep a) Methvl 5-hvdroxv-3-oxotetradecanoate (1a) Fresh NaH (60% dispersion in mineral oil, 0.88 g, 22 mmol) was added under nitrogen toTHF (50 ml) and the suspension was cooled to 0 °C. Methyl acetoacetate (2.16 ml, 20 mmol)was added drop wise while keeping the inside temp below 5 °C. The stirring was continuedat 0 °C for an additional 10 min, then 2.5 M n-BuLi (8.4 ml, 21 mmol) was added drop wise Step c while keeping the inside temperature below 5 °C. The stirring was continued for an additional10 min, then, decanal (3.67 ml, 20 mmol) was added and the reaction mixture was stirred foran additional 30 min allowing the temperature to slowly increase to about 10 °C. The reactionwas quenched, with 6M HCl until acidic followed by addition of water and ether. The waterphase was extracted twice with ether and the combined organic phases were carefullywashed with brine to neutral pH and dried (Na2SO4). After filtration, the organic solvent wasevaporated and a crude product (5.41 g) was obtained. The crude was recrystallized from n-hexanes and after standing at 5°C a first crop of product (1 .6 g) was obtained by transferringthe mother liquid with a thin pipette at °0 C. A second crop (1 _29 g) was obtained giving atotal yield of 2.9 g (53%). 38 Step b) 6-Nonvldihvdro-2H-pvran-2,4(3H)-dione (1b) The compound from step a (1 .61 g, 5.9 mmol) was mixed with 1M NaOH (15 ml). Thereaction mixture was stirred at 0 °C for about 1 h, then 12M HCI (~3 ml) was added and thereaction mixture was allowed to attain room temperature overnight. Water (15 ml) was addedand the mixture was extracted 3 times with DCM. The combined organic phases werewashed with brine, dried (Na2SO4) and concentrated which gave crude title compound (1 .26 g, 89%). The afforded crude product was taken to the next step without further purification.

Step c) 2-Nonvl-6-oxo-3,6-dihvdro-2H-pvran-4-vl butvrate (1c) The compound from step b (1 .26 g, 5.24 mmol) was dissolved in toluene (15 ml) and DBU(1 .18 ml, 7.86 mmol) was added. The reaction solution was cooled to 0 °C and butyrylchloride (0.82 ml, 7.86 mmol) was added drop wise. The reaction mixture was stirred at 0 °Cfor 1 h where after the temperature was allowed to reach room temperature. After 3 hours,water was added and the reaction mixture was extracted twice with ether. The combinedorganic phases were washed with HCI solution, NaHCOs solution and brine. The organicphase was dried (Na2SO4) and concentrated. The afforded crude product was purified on asilica gel column eluted with hexanes/ether 3:1 which gave the title compound (1.18 g,72.5%). LC-MS ES+ 311.07 [IVI+H]*. 1H NMR (400 MHz, CDCI3) ö 7.25, 5.90, 5.89, 4.50, 4.49, 4.48, 4.47, 4.47, 4.46, 4.45, 4.44,4.44, 4.43, 2.68, 2.68, 2.66, 2.65, 2.64, 2.64, 2.61, 2.61, 2.47, 2.45, 2.44, 2.43, 2.41, 2.40,2.39, 2.35, 2.33, 2.31, 2.26, 2.24, 2.23, 2.22, 2.15, 1.86, 1.85, 1.84, 1.83, 1.83, 1.82, 1.81,1.80, 1.80, 1.79, 1.79, 1.78, 1.77, 1.75, 1.73, 1.72, 1.70, 1.68, 1.66, 1.65, 1.64, 1.63, 1.63,1.61,1.60,1.54,1.52,1.51,1.49,1.48,1.48,1.42,1.41,1.39,1.38,1.29,1.28,1.25,1.01,0.99, 0.97, 0.95, 0.93, 0.91, 0.89, 0.87, 0.86, 0.06, -0.01.

Step d) 3-Butvrvl-6-nonvl-4-hvdroxv-5,6-dihvdro-2H-pvran-2-one (1d) The compound from step c (2.5 g, 8.05 mmol) was dissolved in toluene (50 ml) and 4-pyrrolidinopyridine (60 mg, 0.4 mmol) was added. The reaction was heated at 130 °C for 4hrs. The solvent was evaporated and the residue purified on a silica gel column eluted withether/hexanes 1:5 which gave a crude product as a solid (1 .89 g). The solid wasrecrystallized from 10 ml warm hexanes and stored at 5 °C for 3 days. The mother liquid wasremoved by a thin pipette at 0 °C. The crystals were then washed with 1 ml cold hexane. Thewhite crystals were dried in vacuum which gave the title compound (1 .03 g, 41%). The puritywas determined to 99% by LC/UV analysis. LC-MS ES+ 311.2 [l\/l+H]+. 39 1H N|\/IR (400 MHZ, CDCI3) Ö 17.88, 16.18, 7.25, 4.47, 4.45, 4.43, 4.37, 4.36, 4.36, 4.36,4.35, 4.35,4.34, 4.34, 4.33, 4.33, 4.32, 4.32, 4.32, 4.31, 3.08, 3.06, 3.06, 3.04, 3.04, 3.03,3.02, 3.02, 3.00, 2.99, 2.98, 2.98, 2.97, 2.97, 2.96, 2.94, 2.93, 2.92, 2.69, 2.66, 2.65, 2.62,2.61, 2.60, 2.57, 2.56, 2.56, 2.55, 2.55, 2.23, 1.83, 1.81, 1.81,1.80,1.80, 1.79,1.79, 1.78,1.78, 1.77,1.77,1.77, 1.76, 1.76, 1.75, 1.74, 1.74, 1.72, 1.71, 1.71, 1.69, 1.69, 1.69, 1.67,1.67, 1.65, 1.65, 1.64, 1.63, 1.63, 1.62, 1.62,1.61,1.59, 1.58,1.56,1.53, 1.51, 1.50,1.50,1.48, 1.48, 1.47, 1.47, 1.46, 1.45, 1.44,1.42,1.41,1.39, 1.38,1.37,1.32, 1.31,1.28,1.25,1.02, 1.00, 0.98, 0.96, 0.88, 0.87, 0.85, -0.02.

Example 2A & 2B separation of the enantiomers of Compound 1d O OH O OH O OH(E) _ (E) (E)/ Ch|ra| chromatography / /m* (R) + (S) _, o o 8 o o 8 o o 1d 2A 2B Compound 1d (100 mg) was resolved by chiral chromatography using a Lux Cell-3 columneluted with A = hexane, B = 80% hexane, 20% EtOH + 1% TFA. The enantiomeric puritywas determined by an analytical Lux Cell-3 column and the absolute configuration waspostulated based on related Podoblastins cf. J. Pesticide Sci. 13, 605-613 (1988).

Peak 1- comgound 2A: Amount 44 mg, enantiomeric purity 99.9%, [oi]D -31° (c=0.245,DCM), absolute configuration (6R) Peak 2 - comgound 2B: Amount 38 mg, enantiomeric purity 99.8%, [oi]D +33° (c=0.24, DCM), absolute configuration (6S).

Ex. 20, acvlation of compound 1d oo oH O o 01k/ “Eb CIJK/ / 4 o o TEA o o3 8 1a 20 5-Butyryl-2-nonyl-6-oxo-3,6-dihydro-2H-pyran-4-yl propionate (20) Propionyl chloride (0.013 mL, 0.150 mmol) was added at 0 °C to a solution of compound 1d(31.0 mg, 0.100 mmol) in ACN (3.00 mL) and TEA (0.021 mL, 0.150 mmol). The reactionmixture was left at room temperature and stirred for 18h. DCM was added and the solution was washed with water. The organic layer was dried (Na2SO4), filtered and concentrated, which gave the title compound.

Compound 3 to 19 listed in Table 1 below were prepared according to the method describedin Example 1. 1H NMR was ran for the penultimate and last step for Compounds 2-21 and the spectra were found to be in accordance with the spectra for compounds 1c and 1d.

BIOLOGICAL EXAMPLESBioloqical Example 1 - Determination of Minimum lnhibitorv Concentration (lVllC) aqainst Gram-positive pathoqens At first (Table 1), MIC is determined by broth micro-dilution method. The test medium isAntibiotic Medium 3 (AM3; Difco Ltd) mixed with Phosphate Buffered Saline (PBS) inproportions 1:1. Selected MIC values are verified using cation-adjusted Mueller Hinton Broth(MHB; BD). Cell concentration of tested pathogen is adjusted to between 3 and 5 x 105 cellsper ml. To verify cell concentration of tested pathogen, viable cell counts are performeddirectly after each MIC-test by dilution method with PBS as a dilution solvent. Cells arecounted on the agar plates with 50% strength Vegetable Peptone Broth (50% VPB; OxoidLtd) after 16 to 20 h of incubation at 37°C. ln order to establish MIC, appropriate volumes of solutions of test compounds (100, 10, 1and if needed 0.1 ug/ml)dissolved in MeOH are dispensed into wells of 96-wells microtiterplates and the solvent is evaporated. MIC of the test compounds is detected in aconcentration range between 0.05 and 20 pg per ml. Cells of pathogen suspended in testmedium are distributed to the wells and the plates are incubated for 16 to 20 h at 37°C.Negative controls are wells with the test medium only and positive controls are wells with thepathogen in test medium. The MIC is defined as the lowest concentration of each compound with no visible growth of pathogen.

Example compounds of formula I were examined for antibacterial activity against the Gram-positive bacterium Staphylococcus aureus strain LMG15975 using the above describedmethod. Antibacterial activity of the tested compounds determined as MIC is summarized inTable 1. 41 TABLE 1O OO | R2R1 OH Ex. R1 Rz MS [M+H]+ MIC (pg/ml) MIC (pM) CC50 (pg/mL) 1 nonyl propyl 311.2 0.8 2.5 332A nonyl propyl 311.2 1-2 3.2-6.4 272B nonyl propyl 311.2 0.4-0.6 1.3-1.9 253 decyl butyl 339.2 na na na4 1-trans-nonenyl propyl 309.33 0.8-1.2 2.6-3.9 365 nonyl ethyl 297.4 0.65 2.2 50 6 octyl ethyl 283.3 1.2 4.3 55 7 octyl methyl 269.3 2.5 9.3 65 8 nonyl butyl 325.4 50.6 51.9 36 9 nonyl methyl 283.3 1.5-2.5 2.1-4.3 7110 decyl ethyl 311.4 0.4-0.8 1.3-2.6 6011 decyl methyl 297.2 0.8-1.2 2.7-4.0 4012 decyl propyl 325.2 0.6-0.8 1.9-2.6 2513 octyl propyl 297.2 0.8-1.5 2.7-5.1 3014 n6ny| Cyïêffišy* 365.3 0.25 :03 1415 nonyl isobutyl 325.2 0.2-0.4 0.6-1.2 2116 undecyl propyl 339.2 0.1-0.2 na 1917 undecyl butyl 353.2 0.1-0.2 na 1218 nonyl pentyl 339.3 0.6-0.8 na na19 7-cyano-heptyl propyl 308.1 40-50 133-166 >10020 pr6py| 3131 20-30 64-96 60 Comp. Ex. ethyl propyl 212.99 >50 >240 >100 na = not available TABLE 2 42 Antimicrobial Susceptibility Test (AST) by Broth Microdilution Method according to M07-A9 CLSI guidelines.

The tested compounds are as follows:MV085367 R1=nonyl, R2=cyclohexylmethyl; Example 14 MV085483 Räundecyi, R2=MV085485 Räundecyi, R2= propyl; Example 16butyl; Example 17 MV083488 R1=nonyl, propyl; Example 1 O Ai..R1)\/\oH_ MIC (ug/mL)Organism avtrjilhrioitircerreïtišïzaenzie EX 14 EX 16 EX 17 EX 1MV085367 MV085483 MV085485 MV083488 S. aureus ATCC29213 QC strain 2 4 16 4S. aureus MO17 Methicillin-sensitive 1 4 4 2S. aureus PICI Methicillin-resistant 1 4 4S. aureus 7280 Methicillin-resistant 2 8 NTS. epidermis RO7 Methicillin-sensitive 0.5 0.5 0.5 1S. epidermis Staph 1 Methicillin-resistant 0.5 0.5 0.5 NTS. epidermis TA12 Methicillin-resistant 0.5 1 0.5E. faecium 7 Vancomycin-resistant 1 2 1E. faecalis 24 Vancomycin-sensitive 1 1 1E. faecalis 14 Vancomycin-resistant 1 1 1 NTS. aureus LMG 15975 (SLU) Methicillin-resistant 0.25 0.1-0.2 0.1-0.2 0.8S. aureus 4384 (SSI) Methicillin-resistant NT NT NT 2CCSO (ug/mL) 14 19 12 38TABLE 3 Antimicrobial Susceptibility Test (AST) by Broth Microdilution Method according to M07-A9 CLSI guidelines. The tested compound is MV083488 R1=nonyl, propyl; Example 1 in comparison to Ciprofloxacin MIC of the MV083488 (Ex 1) and its selected derivatives (Ex 14, Ex16 and Ex17)(Table 2) is, additionally, determined using the broth micro-dilution method according to M07-A9 Clinical and Laboratory Standards Institute (CLSI) guidelines. All pathogens are tested according toM07-A9 and M26 CLSI guidelines using the appropriate broth medium. Negative controls(lack of bacterial cells) and growth control are included in the plates. S. aureus ATCC 29213and S. pneumoniae ATCC49619 are evaluated as assay quality control strain. The MIC is defined as the lowest concentration of each compound with no visible growth of pathogen. 43 The MIC of MV083488 (Ex 1) is compared to the MIC of ciprofloxacin (Table 3).

Organism Main PheåišåiygpâncïeAntibiotic EX 1M|C (ug/rïl-L) -MV083488 Ciprofloxacin S. aureus ATCC 29213 QC strain 4 0,125S. aureus 4216 Tetracycline-resistant 2 >32S. aureus 853E Macrolide-sensitive 2 0,25S.aureus 6 Holland Macrolide-resistant (M) 1 1 S. aureus 56 Japan Macrolide-resistant (MLSi) 4 >8S. aureus PK2 Macrolide-resistant (MLSc) 2 0,25S. aureus MO 17 MSSA 2 0,5S. aureus PICI MRSA 4 >32S. aureus FR 131 Quinolone-resistant 2 >32S. pneumoniae ATCC 49619 QC strain 4 0,5S. pneumoniae 158bg Macrolide-resistant (M) 4 2S. pneumoniae SP030 Macrolide- sensitive 8 0,5S. pneumoniae 956 Macrolide-resistant (MLSc) 4 1S. pneumoniae 19A-TN Quinolone-sensitive 8 0,5S. pneumoniae TE 122-024 Quinolone-resistant 8 2S. pneumoniae TE 122-026 Tetracycline-resistant 4 1S. pneumoniae BAA1407 Macrolide-resistant (M+MLS) 8 1S. pyogenes 21 Finland Macrolide-resistant (MLSc) 8 0,25S. pyogenes 2 Finland Macrolide-resistant (M) 8 5S. pyogenes 29A-TF Macrolide- sensitive 8 0,25S. epidermidis RO7 MSSE 1 0,125S. epidermidis TA12 MRSE 2 >32E. faecalis E. cocco 24 Vancomycin -sensitive 2 32E. faecalis E.cocco 12 Vancomycin -resistant 2 0,5E. faecium E.coc 7 Vancomycin -resistant 2 >32 TABLE 4 44 Table 4 shows results for MV085367 (example 14) and MV083488 (example 1) testedagainst a panel of Gram-negative bacteria.

Wide range of Gram-negative species pg /mLEN no. Species Other ID MW085367 MW083488EN0454 Serratia marescens G- PKL 3692 > 64 > 64EN0455 Micrococcus luteus G+ PKL 3693 0,5 0,5EN0457 Proteus mirabilis G- PKL 3695 > 64 > 64EN0458 E. coli B G- PKL 3698 > 64 > 64EN0459 P. aeruginosa G- PKL 3699 > 64 > 64EN0460 P. aeruginosa G- PKL 3704 > 64 > 64EN0461 Enterobacter aerogenes G- PKL 3706 > 64 > 64EN0456 S. epidermidis G+ PKL 3694 1 1EN0465 Citrobacter sp. G- PKL 3710 > 64 > 64EN0466 S. typhimurium G- TH6509 > 64 > 64EN0180 A. Pittii/nosocomialis G- > 64 > 64EN0392 K. oxytoca G- > 64 > 64EN0422 P. aeruginosa G- > 64 > 64EN0445 P. mirabilis ST19 G- > 64 > 64ENABLE Primary MIC panel strains pg /mLEN001 E. coli G- WT >64 >64EN002 E. coli G- DtolC >64 4EN003 E. coli G- D22 (lps mut) >64 >64EN004 P. aeruginosa G- WT >64 >64EN005 P. aeruginosa G- Efflux mut >64 2EN006 K. pneumoniae G- WT >64 >64EN007 A. baumanii G- WT >64 >64EN008 S. aureus G+ Gram+ 2 2ENABLE L2C MIC panel strains (isogenic efflux pairs) pg /mL EN0010 K. pneumoniae G- > 64 > 64EN0011 K. pneumoniae G- Efflux mut > 64 8EN0012 E. coli G- > 64 > 64EN0013 E. coli G- Del-tolC 16 0,5EN0014 P. aeruginosa G- > 64 > 64EN0015 P. aeruginosa G- Efflux mut > 64 > 64EN0016 A. baumanii G- > 64 > 64EN0017 A. baumanii G- Efflux mut > 64 > 64 Cytotoxicity assayCytotoxicity of the compounds was evaluated in HepG2 cells as follows: HepG2 (ATCC cat.no. HB-8065) hepatocellular carcinoma cells were maintained inDulbecco's Modified Eagle Medium supplemented with 10% heat inactivated fetal calf serum,penicillin (50 U/ml) and streptomycin (50 ug/ml). Briefly, cells were passaged into 96 wellmicroplates (1 x 104 cells/well) and the next day, test compounds were added in two-foldserial dilutions starting from a final top concentration of 100 ulVl. After another 48 hours ofincubation at 37°, the number of viable cells in each well was assessed by using a water-soluble tetrazolium salt, WST-8 assay (cell counting Kit-8 from Dojindo). The concentration causing 50% decrease in cell viability (CC50) was determined.

Bioloqical Example 2, ln vivo pharmacokinetics The compound of Example 1 was administered orally to triplicate mice in a conventional 20%HPBCD vehicle. Two doses were administered, 10 and 50 ulVl/kg. Blood samples were takenat relevant timepoints over 48 hours, as depicted in the graph below, and the plasmaconcentration of the compound of Example 1 determined by LC/MS/MS. lt will be apparentthat the compound exhibits excellent dose dependent exposure. Macroscopic examination of the animals and their behaviour did not show any sign of adverse effect.

Bioloqical Example 3, ln vitro absorption Permeabi/ity This experiment measures transport of inhibitors through the cells of the human gastroentericcanal. The assay uses the well-known Caco-2 cells with a passage number between 40 and60.

Apical to basolateral transport Generally every compound will be tested in 2-4 wells. The basolateral and the apical wellswill contain 1.5 mL and 0.4 mL transport buffer (TB), respectively, and the standardconcentration of the tested substances is 10 ulVl. Furthermore all test solutions and bufferswill contain 1% DMSO. Prior to the experiment the transport plates are pre-coated withculture medium containing 10% serum for 30 minutes to avoid nonspecific binding to plasticmaterial. After 21 to 28 days in culture on filter supports, the cells are ready for permeability experiments. 46 Transport plate no 1 comprises 3 rows of 4 wells each. Row 1 is denoted Wash, row 2 “30minutes” and row 3 “60 minutes”. Transport plate no 2 comprises 3 rows of 4 wells, one denoted row 4 “90 minutes", row 5 “120 minutes and the remaining row unassigned.

The culture medium from the apical wells is removed and the inserts are transferred to awash row (No. 1) in a transport plate (plate no.1) out of2 plates without inserts, which havealready been prepared with 1.5 mL transport buffer (HBSS, 25 mM HEPES, pH 7.4) in rows 1 to 5. ln A->B screening the TB in basolateral well also contains 1% Bovine Serum Albumin. 0.5 mL transport buffer (HBSS, 25 mM MES, pH 6.5) is added to the inserts and the cellmonolayers equilibrated in the transport buffer system for 30 minutes at 37 °C in a polymixshaker. After being equilibrated to the buffer system the Transepithelial electrical resistancevalue (TEER) is measured in each well by an EVOM chop stick instrument. The TEER values are usually between 400 to 1000 Q per well (depends on passage number used).

The transport buffer (TB, pH 6.5) is removed from the apical side and the insert is transferredto the 30 minutes row (No. 2) and fresh 425 uL TB (pH 6.5), including the test substance isadded to the apical (donor) well. The plates are incubated in a polymix shaker at 37 °C with a low shaking velocity of approximately 150 to 300 rpm.

After 30 minutes incubation in row 2, the inserts are moved to new pre-warmed basolateral (receiver) wells every 30 minutes; row 3 (60 minutes), 4 (90 minutes) and 5 (120 minutes). 25 uL samples are taken from the apical solution after ~2 minutes and at the end of theexperiment. These samples represent donor samples from the start and the end of the experiment. 300 uL will be taken from the basolateral (receiver) wells at each scheduled time point andthe post value of TEER is measured at the end the experiment. To all collected samplesacetonitrile will be added to a final concentration of 50% in the samples. The collected samples will be stored at -20 °C until analysis by HPLC or LC-MS.

Basolateral to apical transport Generally every compound will be tested in 2-4 wells. The basolateral and the apical wellswill contain 1.55 mL and 0.4 mL TB, respectively, and the standard concentration of thetested substances is 10 ulVl. Furthermore all test solutions and buffers will contain 1%DMSO. Prior to the experiment the transport plates are precoated with culture medium containing 10% serum for 30 minutes to avoid nonspecific binding to plastic material. 47 After 21 to 28 days in culture on filter supports the cells are ready for permeabilityexperiments. The culture medium from the apical wells are removed and the inserts are transferred to a wash row (No.1) in a new plate without inserts (Transport plate).

The transport plate comprises 3 rows of 4 wells. Row 1 is denoted ”wash” and row 3 is the“experimental row”. The transport plate has previously been prepared with 1.5 mL TB (pH7.4) in wash row No. 1 and with 1.55 mL TB (pH 7.4), including the test substance, in experimental row No. 3 (donor side). 0.5 mL transport buffer (HBSS, 25 mM MES, pH 6.5) is added to the inserts in row No. 1 andthe cell monolayers are equilibrated in the transport buffer system for 30 minutes, 37 °C in apolymix shaker. After being equilibrated to the buffer system the TEER value is measured in each well by an EVOM chop stick instrument.

The transport buffer (TB, pH 6.5) is removed from the apical side and the insert is transferredto row 3 and 400 uL fresh TB, pH 6.5 is added to the inserts. After 30 minutes 250 uL iswithdrawn from the apical (receiver) well and replaced by fresh transport buffer. Thereafter250 uL samples will be withdrawn and replaced by fresh transport buffer every 30 minutesuntil the end of the experiment at 120 minutes, and finally a post value of TEER is measuredat the end of the experiment. A 25 uL samples will be taken from the basolateral (donor)compartment after ~2 minutes and at the end of the experiment. These samples represent donor samples from the start and the end of the experiment.

To all collected samples acetonitrile will be added to a final concentration of 50% in the samples. The collected samples will be stored at -20 °C until analysis by HPLC or LC-MS.

Calculation Determination of the cumulative fraction absorbed, FACum, versus time. FACum is calculated from: CRI FAcum I TDI Where CR; is the receiver concentration at the end of the interval i and CDi is the donor concentration at the beginning of interval i. A linear relationship should be obtained.

The determination of permeability coefficients (Papp, cm/s) are calculated from: 48 P = (kJ/R)app (A60) where k is the transport rate (min'1) defined as the slope obtained by linear regression of cumulative fraction absorbed (FACum ) as a function of time (min), VR is the volume in the receiver chamber (mL), and A is the area of the filter (cm2).

Reference compounds Cateqorv of absorption in man Markers absorption in man (%)PASSIVE TRANSPORTMannitol 16Low (0'20%) Methotrexate 20Moderate (21-75%) Acyclovir 30_ P I I 90H'9h (76'10°%) clacrllšéfilrèo 0 100ACTIVE TRANSPORTAmino acid transporter L-Phenylalanine 100ACTIVE EFFLUXPGP-MDR1 Digoxin 30 Greater permeability through the gastrointestinal tissue is advantageous in that it allows forthe use of a smaller dose to achieve similar levels of exposure to a less permeablecompound administered in a higher dose. A low dose is advantageous in that it minimizesthe cost of goods for a daily dose, which is a crucial parameter in a drug which is taken for protracted time periods.

The compound of Example 1 exhibited an excellent Caco2 permeability value of Papp 53cmsec'1.

Claims (25)

1. Förening med Formel I: O OR3O Rz R* onf*Formel l i vilken R1 är C2-C20alkenyl innefattande en till tre omättade bindingar; Rz är vald ur den grupp som består av C1-C20alkyl, Cz-Czoalkenyl, Cz-Czoalkynyl, C1-C6alkoxiC1-C3alkyl, cyklopropylmetyl, cyklobutylmetyl, cyklopentylmetyl ellercyklohexylmetyl; Rs är H eller en bindning tillsammans med det närliggande kolet som definierar enkerogrupp, Rfi, c(o)R5, cRaRboRfi, cRaRboc(o)R5, cRaRboc(o)oR5 ellerC(O)CHR7NH2; R4 är RS, c(o)R5, cRaRboRfi, cRaRboc(o)R5, cRaRboc(o)oR5 e||erc(o)cHR7NH2;Rs och RB är oberoende valda ur den grupp som består av H, C1-C6alkyl,Cg-Cßcykloalkyl och Cg-CßcykloalkylC1-C3alkyl; R7 är vald ur den grupp som består av H, C1-C6alkyl, Cg-Cßcykloalkyl och C3-C6cykloalkylC1-C3alkyl; varvid Ra och Rb är oberoende valda bland H och metyl; eller ett farmaceutiskt godtagbart salt, en stereoisomer, en N-oxid eller ett hydrat därav.

2. Förening enligt krav 1, i vilken alkenylen i R1 är substituerad med upp till tresubstituenter oberoende valda ur den grupp som består av halo, -OR5,-c(o)oR5, -c(o)R5, -oc(o)oR5, -NRSRÉ -c(o)NR5R6, -oc(o)NR5R6, nitro, cyano och azido.

3. Förening enligt krav 1 eller 2, i vilken R1 är C6-C12alkenyl, såsom hexenyl, heptenyl,oktenyl, decenyl, undecenyl eller dodecenyl, inklusive sådana som har en omättad bindning, i synnerhet sådana i 1-position.

4. Förening enligt vilket som helst av de föregående kraven, vilken är racemisk vid R1- positionen.

5. Förening enligt vilket som helst av krav 1-3, i vilken R1 är åtminstone 75%enantiomeriskt berikad med avseende på en enantiomer, företrädesvis mer än 90% enantiomeriskt berikad.

6. Förening enligt krav 1, i vilken R1 är 1-trans-nonenyl; Rz är vald bland etyl, propyl,butyl, metyl, cyklohexylmetyl, isobutyl and pentyl; Rs är en bindning som tillsammans med det närliggande kolet definierar en ketogrupp; Och R4 är H.

7. Förening enligt vilket som helst av de föregående kraven, där vilken som helst alkyl,alkenyl, alkynyl, cykloalkyl or cykloalkenyl i Rz är substituerad med upp till tresubstituenter oberoende valda ur den grupp som består av halo, -OR5, -C(O)OR5, -c(o)R5, -oc(o)oR5, -NRfiRâ -c(o)NR5R6, -oc(o)NR5R6, hitro, cyaho och azido, ochdär gruppen också inkluderar C1-C6alkyl eller C1-C6haloalkyl om Rz is cykloalkyl.

8. Förening enligt vilket som helst av de föregående kraven, i vilken Rz är C1-C20alkyl som är substituterad såsom definieras i krav 7.

9. Förening enligt krav 7 eller 8, i vilken Rz är C1-C6alkyl, inklusive metyl, etyl, n-propyl,isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl och n-hexyl, varvid vilken somhelst av alkylerna är substituterad med 1, 2 eller, då valensen så tillåter, 3 substituenteroberoende valda bland C1-C4alkyl, C1-C4haloalkyl, halo, hydroxi, C1-C4alkoxi, C1-C4hydroxialkyl och C1-C4alkylkarbonyl.

10. Förening enligt vilket som helst av krav 1-5, i vilken Rz är C3-C6cykloalkylC1-C3alkylsom är substituterad med upp till tre substituenter oberoende vada bland halo, -OR5, - c(o)oR5, -c(o)R5, -oc(o)oR5, -NRSRÉ -c(o)NR5R6, -oc(o)NR5R6, hitro, cyaho och azido, och om det gäller cykloalkyl, även C1-C6alkyl eller C1-C6haloalkyl.

11. Förening enligt krav 10, i vilken Rz är vald bland cyklopropylmetyl, cyklobutylmetyl,cyklopentylmetyl och speciellt cyklohexylmetyl, varvid vilken som helst cykloalkyl ärsubstituterad med 1, 2 eller, då valensen så tillåter, 3 substituenter oberoende valdabland C1-C4alkyl, C1-C4haloalkyl, halo, hydroxi, C1-C4alkoxi, C1-C4hydroxialkyl och C1-C4alkylkarbonyl.

12. Förening enligt vilket som helst av de föregående kraven, i vilken Rs är en bindning som tillsammans med det närliggande kolet definierar en ketogrupp.

13. Förening enligt krav 1, i vilken Rs är H, inklusive den motsvarande enolen med gammaketonfunktionen på pyranringen.

14. Förening enligt vilket som helst av krav 1-11, i vilken Rs är derivatiserad med enprodrogahhst va|d b|ahd c(o)Rå cRaRboRå cRaRboc(o)R5, cRaRboc(o)oR5 oohc(o)cHR7NH2_

15. Förening enligt krav 11, i vilken: Rs som C(O)Rs har Rs som metyl, isopropyl, cyklopropyl eller terf-butyl, vilken som helstav vilka eventuellt kan vara fluorerad; Rs som CRsRsORs har båda två av Rs och Rs som H, eller båda två som metyl, och Rs ärmetyl, isopropyl, cyklopropyl eller terf-butyl, vilken som helst av vilka kan vara fluorerad;Rs som CRsRsOC(O)Rs har båda två av Rs och Rs som H, eller båda två som metyl, ochRs är metyl, isopropyl, cyklopropyl eller terf-butyl, vilken som helst av vilka eventuellt kanvara fluorerad; Rs som cRaRboc(o)oR5 har bada tva av Ra ooh Rb som H, eller bada tva som metyl,och Rs är metyl, isopropyl, cyklopropyl eller terf-butyl, vilken som helst av vilka eventuelltkan vara fluorerad; eller Rs som C(O)CHR7NH2_ speciellt då R7 är sidokedjan av en L-aminosyra, såsom alanin, valin, leucin eller isoleucin.

16. Förening enligt vilket som helst av de föregående kraven, i vilken R4 är H.

17. Förening enligt vilket som helst av krav 1-14, i vilken R4 är derivatiserad med enprodrogahhst va|d b|ahd c(o)Rå cRaRboRå cRaRboc(o)R5, cRaRboc(o)oR5 oohC(O)CHR7NH2, där Rs och Rs båda är H eller metyl.

18. Förening enligt krav 15, i vilken: Rs som C(O)Rs har Rs som metyl, isopropyl, cyklopropyl eller terf-butyl, vilken som helstav vilka eventuellt kan vara fluorerad; Rs som CRsRsORs har båda två av Rs och Rs som H, eller båda två som metyl, och Rs är metyl, isopropyl, cyklopropyl eller terf-butyl, vilken som helst av vilka kan vara fluorerad; Rs som CRaRbOC(O)R5 har båda två av Ra och Rb som H, eller båda två som metyl, ochR5 är metyl, isopropyl, cyklopropyl eller tert-butyl, vilken som helst av vilka eventuellt kanvara fluorerad; Rs som cRaRboc(o)oR5 har bada tva av Ra och Rb som H, eller bada wa som metyl,och R5 är metyl, isopropyl, cyklopropyl eller tert-butyl, vilken som helst av vilka eventuelltkan vara fluorerad; eller Rs som C(O)CHR7NH2_ speciellt då R7 är sidokedjan av en L-aminosyra, såsom alanin, valin, leucin eller isoleucin.

19. Förening enligt vilket som helst av de föregående kraven, i vilken G1- Cßalkylen eller -cykloalkylen i Rs och RB ä' är substituterad med en eller flera valda urden grupp som består av halo, hydroxi, C1-C4alkoxi, C1-C4haloalkyl, hydroxiC1-C4alkyl,C1-C4alkylkarbonyl, SH, SMe, COOH, COOC1-C4alkyl och CONHZ.

20. Förening enligt vilket som helst av de föregående kraven, i vilken C1-C6alkylen ellerCg-Cßcykloalkylen i R7 är substituterad med en eller flera valda ur den grupp som bestårav halo, hydroxi, fenyl, C1-C4alkoxi, C1-C4haloalkyl, hydroxiC1-C4alkyl, C1-C4alkylkarbonyl,SH, SMe, COOH, COOC1-C4alkyl och CONHZ.

21. Förening enligt krav 1, vilken är (E)-3-butyryl-6-(non-1-en-1-yl)-4-hydroxi-5,6-dihydro-2H-pyran-2-on, eller ett farmaceutiskt godtagbart salt, en stereoisomer, en N-oxid eller ett hydrat därav.

22. Farmaceutisk komposition innefattande en förening såsom definieras i vilket somhelst av de föregående kraven, eller ett farmaceutiskt godtagbart salt, en stereoisomer,en N-oxid eller ett hydrat därav, och en farmaceutiskt godtagbar bärare, vehikel eller spädningsmedel därför.

23. Förening enligt vilket som helst av krav 1-21 för användning som läkemedel.

24. Förening enligt vilket som helst av krav 1-21 för användning vid behandling eller profylax av en Gram-positiv bakterieinfektion.

25. Förening enligt vilket som helst av krav 1-21 för användning vid behandling eller profylax av en Gram-positiv bakteriell kolonisation.